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1. INTRODUCTION 
1.1 Introduction to The Variable-Sample-Size-Sequential PRT (VPRT) 
The theoretical development of sequential theory had its formal beginning with 
the landmark paper by Wald and Wolfowitz (1948). In it, the authors presented the 
sequential probability ratio test (SPRT), a testing procedure, to test a simple null hy­
pothesis against a simple alternative hypothesis, in which a single datum is sampled 
at each time period until acceptance or rejection of the null hypothesis occurs. Their 
procedure is based on whether the hkelihood ratio falls in an acceptance, a rejection, 
or a continue-sampling region at each time period. They established important prop­
erties of this test, most notably, the following two. The SPRT with type-1 error a 
and power 1 — will stop and accept or reject the null hypothesis in a finite time, 
with probability one. The test will have minimal expected total sample size, and, 
equivalently, minimal expected stopping time among all tests with type-1 error less 
than or equal to a, and power at least 1 — 13. 
Similar results were developed independently by Arrow, Blackwell, and Girshick 
(1949), who presented this procedure using a decision-theoretic approach. However, 
both sets of authors considered one-at-a-time sampUng and a potentially infinite 
number of sampling periods. 
More recently, the problem of sampling more than one observation at eaph time 
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period has been considered. This idea includes, most notably, sampling the same 
number of data at each time period, which is known as group-sequential sampling. 
Group-sequential sampling was mentioned by Wald (1947) and Ghosh (1970, p. 224) 
and was first developed for clinical trials by Pocock (1977). The group sample size 
n has been determined in an ad hoc manner or by a variety of criteria. For example, 
some authors chose n such that specified type-1 and type-2 errors were achieved 
within a maximal number of sampling time periods (O'Brien and Fleming, 1979). 
We shall consider inter alia, the problem of sequentially testing a simple null 
hypothesis against a simple alternative hypothesis, but where gains for making the 
right/wrong decision are balanced against the cost of sampling. This will lead to a 
sequential probability ratio test with variable sample size, chosen so that the resulting 
decision procedure is Bayes; call it the variable sample size sequential probability 
ratio test (VPRT). The sample sizes are determined successively at each time period, 
conditional on the data at hand. Work was first done on this by Whittle (1965), 
Spahn and Ehrenfeld (1974), and Cressie and Morgan (1986a, 1988). 
Instead of considering the problem of minimizing a Bayes risk, we instead con­
sider the equivalent problem of maximizing an expected gain function, where the gain 
function can be interpreted as the negative of a loss function (Cressie and Morgan, 
1986a). The VPRT entails expected net gain, which subtracts the cost of sampling. 
This cost must be an unbounded increasing function of n, and it must be on the same 
scale of measurement as the gain function. RaifFa and Schlaifer (1961, pp. 79-86) 
give a detailed discussion of this matter and are particularly helpful in developing 
the idea of costs as the opportunity losses that are an integral component of any op­
timization problem. We consider the class of decision procedures for which sampling 
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is terminated and one of the two hypotheses is accepted at or before a finite prespec-
ified maximal number of time periods. A sequential Bayes procedure is obtained by 
comparing the expected net gain incurred by sampling to that of accepting one or 
the other of the hypotheses. The optimal (Bayes) procedure makes whatever decision 
has the largest expected net gain. Traditionally, the sample size taken is fixed (at 
n = 1); however, the VPRT considers further maximization of this expected net gain. 
The need for choosing optimal sample sizes is obvious, when one considers the 
high cost of clinical trials, and other procedures where the data are extremely expen­
sive. The following situations are natural applications of the VPRT, 
1.Sequential Clinical Trials. 
The gain function could represent the financial gain of testing a drug. This 
could be appropriate for a pharmaceutical company seeking to maximize profits. 
The function could also represent gain, in an ethical sense, to determine whether a 
treatment is worth testing at all, and if so, on how many human subjects. 
2. Industrial Quality Control 
This is a situation in which there is often a well-defined gain function in a 
financial sense, and a known cost of sampling. For an industrial manufacturing 
process, the VPRT could be used, for instance, in destructive testing of the sampling 
units. 
3. Group Testing for at least one individual with a disease. 
Sequential methods have been used in the group testing of samples of blood from 
a group of individuals in order to detect at least one with a certain disease. Great 
economy can be achieved by testing batches sequentially in order to detect at least 
one diseased individual. See Das and Choudhury (1987). 
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4. Oil Exploration. 
Geological evidence may suggest that a particular area of land contains n undis­
covered sources, with considerable expense of exploratory drilling. Bayes sequential 
methods can be used to sample (drill) in a manner so as to maximize the profits of 
the company owning the land. See Benkherouf and Bather (1988). 
1.2 Sequential Hypothesis Testing: A Selected Literature Review 
In this dissertation we show the advantages of sample-size optimization in se­
quential hypothesis testing. There is a large amount of literature on sequential hy­
pothesis testing, so we will discuss only those articles for which sample-size opti­
mization and other ideas from the VPRT have some relevance. These include both 
frequentist and decision-theoretic ideas. We shall discuss at length tests intended for 
sequential clinical trials. For general reference books on clinical trials and statistics 
in medical research see Armitage (1971), Friedman, Furberg, and DeMets (1982), and 
Whitehead (1983). These include, most notably, repeated significance tests (RSTs) 
which are tests based on retesting the accumulating likelihood ratio. Group-sequential 
tests are a special class of RSTs in which the same sample size n is assayed at each 
stage at which sampling is continued. Such tests include two-arm trials to assess 
the efiicacy of a new therapy relative to a control. In group-sequential trials of the 
latter type, the two arms of the trial would have perhaps different sample sizes 
and where 'ctl' means 'control' and 'trt' means 'treatment'. But, in a group-
sequential procedure, these sample sizes would be the same at all stages. Further 
discussion of RSTs and group-sequential trials is deferred to Section 1.2.2. 
This dissertation will focus on the testing of a simple null hypothesis versus a 
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simple alternative: point and interval estimation will not be discussed. Only exact 
results will be presented; for sequential asymptotic theory, see Siegmund (1985). We 
shall examine multi-stage procedures in which time is discrete, where the number of 
stages is fixed in advance. 
Minimizing total sample size has been used as a design criterion. The original 
work on this was done by Wald and Wolfowitz (1948), who proved that the SPRT 
has minimal sample size among all procedures with type-1 error < a and type-2 error 
< 1 — TT, with a and tt specified. The idea of optimizing over sample size has been 
considered in the literature for special cases. See DeGroot (1970, pp. 233, 247-249), 
Hcdd (1981, Section 7.4), and Berger (1985, p. 439). 
Thall, Simon, Ellenberg, and Shrager (1989) considered a two-arm, two-stage 
procedure with Bernoulli data. They minimized the expected total sample size N = 
riQ+ni, where ng and nj^ are the sample sizes taken at stages 0 and 1, respectively. 
They considered a simple null hypothesis of no treatment difference versus a simple 
alternative A = ~ '^ctb where w is the Bernoulli parameter, and minimized 
E{N) = (1/2) (EQ{N) + subject to the usual constraints on A and /3. 
They did this by searching over all possible values of nQ,n^, and pairs of 
critical points for the standardized Gaussian statistics at if = 1, 2. We can generalize 
this to make use of a two-point prior pQ, as in the VPRT, with pg necessarily 
1/2. Their procedure has both high power and a high probability of terminating 
early when the null is true. 
Fleming (1982) devised a test for the sequential testing of a Bernoulli parameter 
w in a one-arm procedure. He had a fixed total sample size, a specified a-Ievel, 
and a specified value for HQ : w = wg. For illustration, he computed the alternative 
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parameter with the ad-hoc requirement that the type-1 and type-2 errors be equal 
to each other. 
1.2.1 Decision-theoretic procedures 
In the formulation of the VPRT, to be presented later in this chapter, we shall 
define a gain function with values corresponding to various decisions and states of 
nature. With this gain function we will have a notion of expected gain to be had by 
taking a sample of data. Finally, we will consider expected net gain, the expected gain 
less the cost of sampling. This leads naturally to the idea of maximizing this expected 
net gain over all possible sample sizes. In this section we describe Some representative 
procedures from the literature, for which this idea has relevance. Although they differ 
substantially, they all have in common a notion of gain and a cost function, or can 
be reexpressed as such. Most did not consider optimizing on sample size, but could 
have. For these reasons, the following literature review has relevance to the VPRT. 
The use in sequential sampling of a critical point for pg, the prior probability 
that the parameter of a distribution takes on a particular value, was considered 
by Cornfield (1966). One of the first papers to address many of the VPRT ideas 
was written by Ehrenfeld (1972). He considered a simple null hypothesis versus 
a simple alternative, and a two-point prior for the truth or falsehood of the null. 
Most relevant to our study, he optimized the expected loss plus the expected cost of 
sampling, optimizing on sample size. He proved the existence of upper and lower 
continue-sampling points for the prior pQ, and used backward induction. The paper 
has, however, a misleading title : "On Group-Sequential Sampling", a use of the term 
'group-sequential' not consistent with its contemporary use. 
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Adaptive procedures are controlled clinical trials that seek to maximize the sum 
of the number of study subjects, plus those at risk not participating in the study, 
who receive the better therapy. This total can be thought of as the gain; choosing 
a sample size that maximizes this gain implies an n-optimization for this criterion. 
The idea is to address the problem of ethics toward the study subjects, and the 
population at risk. The latter is known in the literature as the 'patient horizon'. 
This requires an assumption about the total number N of people at risk (or, with 
a disease). This number is perhaps large but finite. An early paper to address the 
idea of using expected net gain and n-optimization is by Colton (1963). This author 
defines a notion of net gain, and optimizes over sample size, in an adaptive two-arm 
procedure intended to give the better of the two treatments to as large a group of 
study subjects as possible. Problems of this kind are discussed by Berry and Fristedt 
(1985). A good survey paper of sequential methods, including ethical issues, is given 
by DeMets and Lan (1984). 
Sylvester and Staquet (1980), and Sylvester (1988) consider a Bayes approach 
to the testing of a Bernoulli parameter, with a simple HQ versus a simple a 
Bernoulli prior, and sample-size optimization. Their loss function is proportional to 
the costs of treating patients, depending on the efficacy of the treatment and the 
decisions to accept or reject it. Their design entails those in the trial and those in 
the 'patient horizon'. They minimize their risk function over sample size and over 
the discrete set of possible critical points for the binomial sum of observations. 
Berry and Ho (1988) present a Bayes sequential procedure for the testing of 
(composite) hypotheses in a pharmaceutical-trials setting, where sample size is as­
sumed given. Let and be the means for the control and treatment groups 
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respectively. Let 
^ = Hrt - t^ctl 
be the parameter of interest, called the 'efficacy' of the new treatment vis à vis the 
control; a positive value of 6 corresponds to preference for the new treatment. They 
use a piecewise linear loss function, with the loss proportional to the efficacy 8. Their 
procedure uses as its risk function the expected loss plus the cost of sampling. It 
illustrates a class of problems in which the gain is proportional to the efficacy <5, 
of the new treatment relative to the control. Although they did not optimize on 
sample size dynamically, as do Cressie and Morgan, they could have. The notion 
of n-optimization is relevant to the Berry-Ho procedure. The study of what can be 
gained by optimizing on sample size is the subject of Chapter 3. 
Cohen (1986) gives a Bayes procedure, considering the cost of sampling and 
0 — 1 loss, for Gaussian data with a conjugate Gaussian-gamma prior. This can be 
seen as a VPRT-like procedure with a given set of gain parameters. The expected 
sum of gains less the average number of observations needed to reach a decision was 
considered by Dunnett (1960). In the sense that he considered an expected gain less 
a cost of sampling, he has presented a VPRT-like procedure. He developed his Bayes 
procedure for the in-vitro screening of a large number of drugs. 
A nonsequential Bayes procedure maximizing expected gain less the cost of sam­
pling is presented by Barenghi, Aczel, and Best (1986). 
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1.2.2 Repeated significance tests (RSTs) 
1.2.2.1 Introduction Researchers often conduct experiments in which data 
are acquired over a period of time, whether by design or due to natural accumulation. 
Their intention may be to perform a single hypothesis test on all of the data when 
it arrives, but they have a curiosity, and often a responsibility to take early periodic 
'looks' at the data at intermediate time points. This creates statistical dilemmas 
of retesting the accumulating data; specifically, the sequence of tests are dependent, 
and the type-1 error a of the procedure usually exceeds the nominal level desired. 
These problems are well-understood by statisticians (e.g., Armitage, McPherson, and 
Rowe, 1969), but they are poorly understood by many scientists. Hence, there is a 
need for appropriate sequential designs. It should be noted that some Bayesians 
do not believe that this inflated-a problem should be a design consideration, since 
they justify inferences based on the likelihood principle no matter what the design. 
They dismiss the optional stopping problem as irrelevant since inferences based on 
the likelihood principle are unaffected by stopping rules. This is discussed by Berry 
(1987b). 
There is also a need to end a procedure early if the evidence in the data is 
overwhelming for the truth of a hypothesis. This may yield large savings in lives, 
effort, time, and money (e.g., in clinical trials). In clinical trials, there is an ethical 
imperative to stop a trial early if the treatment being tested is no better than the 
control, or much worse. On the other hand, if a tested treatment shows early promise 
of achieving a medical breakthrough, there is a responsibility to serve the people at 
risk who are not in the trial (i.e., the 'patient horizon'), who could perhaps benefit 
greatly. The benefit of early stopping may be financial, as well as ethical if, for 
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example, a new drug would be profitable to a pharmaceutical company; 
For many procedures, the data gathered are modeled as Bernoulli or Gaussian, 
where the accumulating sum of observations is the sufficient statistic. This section 
addresses the problem of design of procedures for such situations. It does not address 
problems of the type in which there is a long time lag between subjects being assayed 
and the results being obtained. The latter class of procedures includes, for instance, 
survival studies of cancer patients who are given experimental treatments. But even 
for these, sequential trials can be planned. 
Repeated Significance Tests (RSTs) have a long history in the literature. They 
are also the procedures used most frequently in practice, in medical research. This 
dissertation attempts to show that thinking in terms of gains and losses (cost of 
sampling) might be more relevant for the planning of clinical trials, than the con­
sideration of tail probabilities. It also attempts to show, if one adopts this way of 
thinking, that greater expected gains can be had by optimizing on sample size. For 
this reason, clinical trials in general, and especially RSTs, have a special importance 
for us. The important issues of design of RSTs, and the most important ones shall 
be discussed. 
This section will focus on those that consider repeated significance testing of 
an accumulating sample mean, where possibly more than one observation at each 
time period can be obtained. These include mostly two-arm procedures, in which a 
new treatment is compared to a control, with a decision made about which is better 
up to a finite number T of sampling periods. Armitage, in the first edition of his 
book Sequential Mediccd Trials (1960, reprinted in 1975), was the first to use the 
term RST. He took it to mean procedures with a fixed constant level of rejection. 
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using the standardized accumulating sum at each time period, so as to achieve a pre-
specified type-1 error. The term has since been used to include all sequential plans in 
which the accumulating sum (or, equivalently, sample mean) is retested at each time 
period. The advantage of such plans is that an upper bound on time and sample 
size can be fixed in advance. Although these procedures may find use in nonmedical 
settings, medical terminology will be used since many of the procedures described 
were developed for medical appUcations. 
Many of the RST procedures test the null hypothesis that the treatment mean is 
the same as the control mean, where the common mean is unspecified. The alterna­
tive hypothesis is that the means are not the same. Some of the trials are 'one-sided'; 
the alternative is that the treatment mean is greater than the control mean, positive 
values indicating the relative effectiveness of the experimental therapy. These proce­
dures are also planned to have a maximal finite number T of time periods for testing. 
Most designs for medical trials described in the literature consider T to be at most 
five. Among these are procedures in which an equal prespecified number of subjects 
are assayed at each time period, although the two arms of the trial may have different 
numbers of subjects. Such procedures are called group-sequential tests. Some RSTs 
test a simple null hypothesis versus a simple alternative, in which a pair of success 
probabilities or Gaussian means are specified by the hypotheses. Such procedures 
can be compared numerically to the VPRT if an appropriate gain function can be 
specified. 
Repeated Significance Tests as a group do not address the issues with which we 
are concerned; sample-size optimization in a Bayes sense, the notion of gain to be 
acquired by assaying a treatment, or loss incurred by the cost of sampling. In this 
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section we point out the issues aad optimizations considered in procedure designs of 
some authors. We also point out useful ideas they could have considered, but did 
not, such as sample-size optimization. The procedures reviewed all have relevance 
to the VPRT, and this will be discussed. It is also iinportant to discuss how the 
hypotheses of the RSTs (in the sense of Armitage) differ from those of the VPRT. 
A two-arm clinical trial has, for observations in the control and treatment groups, 
parameters and respectively. The null hypothesis is, HQ : 
The composite alternative considered is Hi : ^ 0^^^, or Hi : — O^fil > 
S, where 6 is a given positive constant. In such a setup, we have stop/continue 
critical points for the accumulating sample mean. We have a middle region in which 
sampling is continued. This region is bounded by critical points for acceptance of 
the alternative hypothesis Hi- The RST setup does not allow early termination due 
to acceptance of the null hypothesis of no treatment difference, as does the VPRT 
procedure. For comparability to the VPRT, a RST might be approximated by a test 
of HQ : 0TRT—^CIL ~ versus HI : ^TRT — ^CTL ~ ^ positive constant S. Such a 
procedure would allow early stopping due to acceptance of the null hypothesis. The 
middle 'continue-sampling' region would then correspond to no decision for either 
hypothesis. 
An important design consideration is the choice of critical points and correspond­
ing rejection probabilities. If the continue-sampling intervals for the accumulating 
sample mean are wide in the early stages and narrow with increasing time, then spu­
rious early rejection will be unlikely. The critical points can be chosen to meet certain 
design requirements, such as a minimal average sample number (ASN) or a desired 
rate of a-spending. Many of the procedures have in common the property that the 
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critical points are chosen so as to achieve an overall specified type-1 error. With this 
constraint satisfied there is still a continuum of design possibilities, allowing for other 
design criteria to be met, such as maximizing the overall power. None of the RSTs 
optimize, in a Bayesian sense, on sample size, but some choose an n common to all 
time periods so as to meet design constraints. 
1.2.2.2 Standard notation for RSTs There is no standard notation in 
the literature for RSTs, but there seems to be a consensus for the following notation, 
taken from the books by Armitage (1975) and Whitehead (1983). 
We shall let (w) be the joint probability of arriving at stage t and rejecting 
HQ at that stage, conditional on the true value w, when there are at most T stages. 
This is the joint probability that the accumulating likelihood ratio passes through 
continue-sampling 'gates' (critical points) at all stages before the t-th stage, and then 
crosses a critical point at the t-th stage, such that HQ is rejected. We shall let AJ' (w) 
be the probability of rejecting HQ at or before stage t, conditional on w, when there 
are at most T stages. Formulas for these will be given in Section 1.6. We shall let 
i/J'(w) be the "nominal" two-tail level of rejecting the null hypothesis, conditional 
on w, for a nonsequential procedure based on a centered and scaled sample mean 
from a Gaussian distribution (e.g., based on a test statistic which is distributed as 
Gau(u}, 1)). So, for instance, for the null hypothesis HQ : w = 0, (0) = .05 and 
n = 1 corresponds to the critical points ±1.96. Scientists not familiar with sequential 
theory (the optional stopping phenomenon of Armitage, 1975, p.29) might assume 
incorrectly that i/^(0) is the true level of rejection, whereas oc^{0) is. For several 
procedures in the literature, critical points are found for a prespecified set of values 
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of (w). 
To allow comparability, we shall consider procedures with Gaussian data and a 
known variance cr^. Let be the sum of Gau(0,<7^) observations obtained at 
t 
the i-th stage, and define X^, to be the accumulated sum of Gaussian data 
2=1 
obtained at the t-th stage. For presentation we shall use this scale (this is consistent 
with notation in Whitehead, 1983). We shall let be the critical point of 
Expressing it in terms of (0), we define (J' via Pr{\Zf \ > cj'|^o) = vj(0). It is 
easy to show, for unit sampling at each stage, that (l — (0))-
Let uj" = Zil{t^l'^ar). It is the standardized (scaled) counterpart of It has a 
Gaussian distribution with a nominal mean of zero and unit variance. Critical points 
in the scale of uj" shall be denoted as uj' (not to be confused with of the VPRT 
formulation). Expressing it J" in terms of f/^(0), we define it via Pr(\U^\ > uj" ) = 
vj(0). It is easy to show that uj = (l — {ofj. For all discussion of testing 
of a success probabilities w we shall use the (0,1) parameterization, not (—1,1). The 
Gaussian mean parameter will be denoted by fi. 
1.2.3 Literature review of RSTs 
An excellent discussion of group-sequential procedures has been presented by 
O'Brien (1990). We describe several of the most important procedures in the litera­
ture, focusing on general ideas used in all RSTs. 
1.2.3.1 Armitage's procedure Armitage (1960, 1975) was the first to pro­
pose the use of RST procedures. For an overall type-1 error a, he suggested using 
a fixed level aj"(0) = a' < a, < T. Instead of fixing the truncation time T, 
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he computed it so as to achieve specified type-1 and type-2 errors. His procedures 
are not particularly well-suited for clinical trials, since he considered only unit sam­
pling, taking as a "unit" a group of subjects. Predating Armitage's work were the 
Restricted Sampling Procedures (Bross, 1952). These procedures tested the null hy­
pothesis of no difference between treatment and control means versus the alternative 
of a treatment difference, as did Armitage. He considered unit sampling and a finite 
truncation time, T. Using the running sum of observations as the test statistic, the 
critical boundaries of the procedure were straight lines. Armitage saw no advantage 
to straight line boundaries, and preferred a constant small level of rejection at all 
time periods, necessitating curved stopping boundaries for the accumulating sample 
sum (Armitage, 1975, pp. 32-34, 103-107). 
1.2.3.2 Pocock's procedure Pocock (1977) first developed RSTs for use in 
frequentist clinical trials assuming Gaussian data with known variance. He developed 
procedures with a fixed time horizon T, a fixed maximal total sample size N, and 
specified type-1 and type-2 errors. His tests had two treatments and a null hypothesis 
of no treatment difference. His procedures did not, however, allow early stopping due 
to no apparent treatment difference. By also specifying simple null and alternative 
hypotheses, and fixed overall type-1 error and power, he was able to solve for Uf = n, 
the constant sample size used at each stage. His critical points for the accumulating 
standardized mean were the same at all stages, such that the overall type-1 error was 
the specified value of a. The final stage T had an indifference region for the Gaussian 
statistic. Thus, if the truncation stage T were reached, then one would conclude that 
one treatment arm was better than the other, or that they did not differ significantly. 
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This is in contrast to the VPRT setup, in which the 'continue-sampling' region at 
stage T is a single point; hence, a simple decision for one or the other hypotheses 
must be made if stage T is reached. This plan has, in the opinion of some researchers, 
too great a tendency for spurious early rejection of the null hypothesis. 
His general idea of symmetric two-sided testing of the hypothesis of no treatment 
difference has since been examined by other authors, who had various criteria for early 
stopping. For a numerical comparison of the best known related procedures, and a 
discussion of the issues involved, see Geller and Pocock (1987). They also give an 
extensive bibliography. 
1.2.3.3 O'Brien and Fleming's procedure A two-arm procedure with a 
fixed type-1 error, 0-1 data, and small probability of stopping early was developed 
for use in medical trials by O'Brien and Fleming (0-F) (O'Brien, Fleming, 1979). 
Their procedure tests the hypothesis that the success probabilities in a two-arm 
procedure are equal, but unspecified, versus the hypothesis that they are not equal. 
They considered T < 5 and sample sizes fixed in advance. These group sample 
sizes are the same at all time periods of the trial, but not necessarily the same for 
the two treatment groups. Hence, the 0-F procedure is a group-sequential trial. To 
address the problem of spurious early rejection of the null hypothesis based on a small 
amount of data, they developed a procedure with extremely wide continue-samphng 
intervals in the early stages, which narrow down rapidly as the time t increases. 
Such a procedure allows early stopping, but only if the early evidence for rejection 
is extreme. The procedure is appealing to practitioners since the test statistic is the 
usual statistic using all the data from the accumulating two by two table. One 
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can equivalently look at the accumulating difference of sample means with symmetric 
critical points about zero. For the standardized difference of sample means there are 
continue-sampling intervals at all time periods but the last. Before T is reached, 
there are three possible decisions; to continue sampling or to conclude that one of the 
treatments is superior to the other. The procedure may stop early due to rejection 
of the null hypothesis of no treatment difference. If the final stage T is reached, the 
three decisions possible are that the treatments do not differ or that one is superior 
to the other. The 0-F procedure is not comparable to the VPRT in that it hcis 
three decisions possible at its time endpoint. The critical points for the standardized 
difference of means have the form times a constant for i = 1, • • •, Z". The 
function seems to be a reasonable, if ad hoc, choice of a decreasing function 
of t. 
The procedure has a type-1 error equal to a prespecified value a with power 
levels also the same as for the corresponding nonsequential test on all the data. 
This is one of several RSTs designed to discourage early rejection except in the 
face of overwhelming statistical evidence. A VPRT could be planned to discourage 
early rejection if desired. This could be done by letting U^QO increase as t 
increases. The expected net gains attained by continuing to later stages would then 
increase, making early rejection less likely. If the parameters are such that the 
overall type-1 error is a specified value a, then early rejection would be less likely. 
These are conjectures needing future research. 
1.2.3.4 Other procedures Peto et al. (1976) described a truncated proce­
dure, for Gaussian data, similar to that of Pocock; critical points are constant and 
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symmetric about zero for the standardized mean; t = l,*'-,r — 1. But the critical 
point at stage T is zero, forcing a decision for one treatment or the other (eliminating 
Pocock's indifference decision at stage T). Their critical points were chosen in this 
manner so as to achieve an overall type-1 error a under the hypothesis of no treat­
ment difference. Their procedure has a probability of early rejection intermediate 
between that of 0-F and Pocock. 
Fleming, Harrington, and O'Brien (1984) described group-sequential procedures 
to test a simple null hypothesis versus a simple alternative. Most of the other group-
sequential procedures seen in the literature are for testing the equality of means or of 
success probabilities. The composite alternative for most of these other procedures 
is that the parameters differ. This procedure, henceforth known as FHO, can in 
principle, be directly compared to the VPRT, since it tests a pair of simple hypotheses. 
They propose a frequentist procedure in which the overall type-1 error, and the finite 
truncation stage T, are specified in advance. They specify af (0), the joint probability 
of arriving at stage t and rejecting the null hypothesis at that stage, as a constant; 
t < T. These probabilities are defined in (1.12.) The FHO procedure differs from 
the Pocock procedure in that these authors do not allow an indifference decision if 
the truncation stage is reached. Then, c^(0) = a — const • {T — 1). The FHO 
procedure allows for changing the truncation stage T while the trial is in progress, 
for reasons that are not data-dependent. It also has the advantage of having nearly 
the same power as that of a nonsequential procedure performed if stage T is reached. 
FHO assume that the observations Zj are Gaussian, with Var{Zj) = j/T times a 
constant, as do 0-F. They solve for critical points {u^} in the standardized Gaussian 
scale, recursively, using numerical integration. Their paper has tables of i/J'{0), the 
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nominal standardized level of rejection for levels of both a and truncation stage T. 
We could formulate a VPRT procedure with the requirement that U^QO ~ "fib 
= 0 = UfOb and that matches that of FHO. Then we could find a value 
of u^Qo such that a^(0) = a, the value of the type-1 error used by FHO. Such a 
procedure would then match that of FHO in overall type-1 error. The correspondence 
between the Gaussian-scale critical values of the FHO procedure, and that of the 
VPRT, is obtained using (2.24) and (2.25). Of course, our vector of critical points in 
the standardized Gaussian scale would not match theirs. But, our procedure would 
have the advantage of being Bayes-optimal for the value further, this value 
u^OO kas a useful real-world interpretation, then we have presented a procedure with 
maximal benefit (gain) with a satisfactory type-1 error. If it happens that the sample 
sizes obtained are acceptable to the cUent, then we will have formulated a procedure 
that perhaps better satisfies his needs than any group-sequential procedure with ad 
hoc sample sizes. This could be the subject of future research. 
One-sided procedures have also been considered. DeMets and Ware (1980) de­
veloped a procedure that allows early acceptance of the hypothesis of no difference 
of treatment means. This is in contrast to most other group-sequential procedures, 
which continue to the truncation stage if there is no early evidence of a treatment 
difference. They used asymmetric boundaries, among other choices, for the testing of 
the difference between Gaussian means. These authors suggest three ad hoc choices 
of boundary points, and discuss the merits of each. Theirs is one of the few pa­
pers to consider a one-sided alternative to a control therapy in a two-arm sequential 
procedure. 
Slud and Wei (1982) described a method to find critical points of a procedure 
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in a general setting in which the sequence of levels of rejection of the 
null hypothesis, given it is true, are specified. Their procedure was described for 
a multivariate Gaussian distiribution in which the distribution of (Zi, - • •, Zf), for 
t < T, is known. These critical points are found recursively by numerical integration, 
using the Equations (1.40). 
In a truncated sequential procedure, the overall type-1 error is often set at a 
particular value a. With this constraint, various design criteria have been considered, 
leading to sequences of probabilities of rejection. These are denoted as (w), and 
were defined in Definition 1.13. This sequence starts at a^(0) = 0 and increases to 
a^(0) = a if the truncation stage is reached. These probabilities can be computed for 
a given sequence of sample sizes and critical points. Lan and DeMets (1983) suggest 
instead fixing the sequence of probabilities aj'(w), and computing from these the 
sequence of critical points, that a procedure could be designed so as to encourage or 
discourage early rejection of HQ, according to one's particular needs. The authors 
refer to this idea as a-spending. They suggest three functions of continuous time such 
that (w) = 0 and a^(w) = a. Their approach generalizes that of Slud and Wei 
(1982). 
K a sequential clinical trial is in progress, accumulated data might suggest that 
one of two hypotheses will be accepted by the truncation stage, with high probability. 
If the purpose of the investigators is to determine which of the two hypotheses is 
true, and as soon as possible, then it makes sense to stop the trial early, based on 
the interim data. This idea can be incorporated into the design of a clinical trial. 
This is known as stochastic curtailing, and has been considered by Lan, DeMets, and 
Halperin (1984). 
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Wang and Tsiatis (1987) considered the testing of the null hypothesis of no 
treatment difference for a two-arm procedure. They presented a family of procedures 
in which rejection occurs if \zj'| > const • i = 1, • • •, T. They examined this for 
A G [0,1], noting that 0-F used A = —.5, and Pocock used A = 0. They found A 
for fixed T, type-1 and type-2 errors such that the average sample number (ASN) is 
minimal. 
1.3 Sequential Testing Procedure: Structure and Notation 
1.3.1 Sequential decision rules 
Let 0 = {wo,wi} be a two-element parameter space of the states of nature. 
We wish to decide which of the two simple hypotheses, 
HQ : w = WQ, versus : a; = wj, (1.1) 
is true. Let X be the space of possible observations with a cumulative distribution 
function (cdf) F{x\uj)\ x & X and w € f2. We may sample from the distribution of 
X in order to choose between wg and . Let f be the Radon-Nikodym derivative of 
F with respect to a dominating measure, here either Lebesgue measure or counting 
measure. Let T denote the number of decision periods available to the decisionmaker, 
not necessarily equally spaced in time. Let t 6 {0,*••,7'} denote the t-th decision 
point, 1 < T < oo. If T < oo we have a truncated procedure. The time period t=0 
is the planning stage. A decision about the true state of nature can be made at any 
of the periods < = 0,1, " , T —1, but a choice between wg and must be made by 
the last stage T. Let pQ be the (Bernoulli) prior probability that the event WQ is the 
true state of nature. 
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Observations Xf = , • • •,are requested at stage t, collected between 
t and t+1, and received by the decisionmaker at stage t+1. We have a cost function 
for collecting n observations at stage t, Cf(n), paid at stage t. We assume that when 
no observations are taken (i.e., = 0), then C((0) > 0. We further assume that 
ci{n) is an unbounded monotonie strictly increasing function of n, for all < > 0. The 
data vector contains the accumulated data available at stage t. It is updated at 
stage t+1 to include the new information 
W = ° (1.2) 
Define to be the range associated with the information vector f = 0, • • •, T". 
A (sequential) decision rule to choose between WQ or consists of a stopping 
rule, a sample-size rule, and a terminal decision rule. 
Definition 1.1 A terminal-decision rule A is a sequence {A^}^Q where A( : 
—» {0,1}; HQ is chosen ^ A^(-) = 0, and is chosen if AF{-) = 1. 
Call A® the space of terminal decision rules. 
Definition 1.2 A gain function at stage t is a mapping : 0 x {0,1} —» %, where 
Q = {wQ, } and 
Uti<^,^tiyt)) = " 
«<00 ; ^tivt) = 0 and UJ = UJQ 
«<01 I if ^tivt) = 0 andu) = u}i 
«<10 ' if^tivt) = 1 andui = UQ 
«<11 ' = 1 anduj = uji 
; < = 0, - ,T, (1.3) 
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and each is assumed to be finite. Typically, a gain function has the properties 
that u^oO ^ UfiO and Ufw > u^Ql' since correct decisions are usually rewarded 
more than incorrect ones. In the class of procedures that we shall consider, early 
termination is possible. All of our procedures compare the expected gain of stopping 
at any stage t with the expected gain, net of costs, of continuing to the next stage, 
< + 1. We can also discount the expected gain net of costs by a factor r G [0,1]. 
Definition 1.3 A discount factor r 6 [0,1] is a constant multiplier of the expected 
gain, net of costs, of continuing to sample. 
Definition 1.4 A sample-size rule $ is a sequence where V'i : —* 
U {0}, the set of nonnegative integers; ipj'i-) = 0. 
Call the set of sample-size rules. 
Definition 1.5 A stopping rule S is a sequence {SF}JLQ where SF ; —> {0,1}. 
Sampling continues at stage t if Sf{-) = 0, and a terminal decision is made at t if 
^ti') = 1; ^T(') = 
Call 5^ the space of stopping rules. 
Definition 1.6 A sequential decision rule d = (5,^, A), is an ordered triple 
composed of a stopping rule S, a sample size rule and a terminal decision rule A. 
Call D = 5"^ X X A^ the space of sequential decision rules. 
The goal here is to establish thé existence and form of a decision rule d* € D 
that yields the highest expected gain net of costs among all rules d 6 D îor choosing 
between WQ and , which we have seen could be called a Bayes rule. The considerable 
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breadth of the space D is best illustrated by considering some of its members. The 
class of purely sequential one-at-a-time-sampling decision rules correspond to ^^(•) = 
1 if sampling continues at stage t, and 0 if not; i = 0, * * •, T—1. The class of one-stage 
test procedures is defined by restricting St(-) = 1; i >1, and the class of two-stage 
procedures is defined by restricting St(-) — 1; t > 2. Clearly, these are just a few of 
the many types of rules found in D. 
The relative benefits of this n-optimization will be examined, and compared 
to one-at-a-time sampling. Any procedure with one-at-a-time sampling will hence­
forth be known as a truncated (in total sample size) sequential probabiUty ratio test 
(TPRT). 
Définition 1.7 Any sequential sampling procedure in which the sample sizes = 
1, Vf G {0, • • • ,r — 1} will be known as a truncated sequential probability ratio 
test (TPRT). 
1.3.2 Optimal decision rules 
In this section a gain function will be defined. A procedure that maximizes the 
expected gain less the cost of sampling will be a Bayes procedure. As part of the 
notational development, we give the decision rule that is optimal (Bayes). A proof 
of this optimality is given in Cressie and Morgan (1989b, Section 4.3). 
Let pf be the decisionmaker's posterior probability at stage t of the event w = WQ . 
By Bayes' Theorem, for f = 0, • • •, T — 1 and > 0, 
^ /W;wo)p( 
fixf,u;Q)pt +f{xf,ui){l-pt) 
= fiyt+v'^o)po , (14) 
/(2/<+i;^o)po + -po) 
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where /(•) represents the density (or probability mass) function of its argument. If 
rn = 0, then Pt^i = Pt\ ^ E {0, — 1}. Also, the unconditional cumulative 
distribution function (cdf) of a:^ at t is, 
^tin) = + (1 - ). (i.5) 
Let d E D, where the class D of sequential decision rules was defined in Section 
1.3.1. Let pf be the posterior at stage t\ i = 0, • • •, T, and let be the data vector 
obtained at stage t, and defined in (1.2). Let Vf {yiid^pi) be the expected gain, at 
stage t, of the decision rule d with data vector and posterior pf. We shall now 
define an optimal decision rule in this class D. 
Definition 1.8 A decision rule d' £ D is optimal if, for any p^ E [0,1], 
^ V?{yhd,pt),'i deD] < = 0, - ,T. 
The dynamic-programming approach is used in the following analysis; the classic 
references in its vast Uterature are the books of Bellman (1957) and Bellman and 
Dreyfus (1962). An expected-net-gain maximization rule is achieved by choosing the 
stopping rule, the sample-size rule, and the terminal-decision rule that maximizes 
the expected gain net of costs at each stage of the sequential procedure. Backward 
induction (e.g., Raiffa and Schlaifer, 1961, p. 7) is the technique that implements the 
analysis. 
At stage t, the expected net gain from a terminal decision procedure is, 
Moo(i - ^tivt)) + Pt 
+ {mi('^-^tiyt)) + mi^t{yt)}i^-Pt)- . (i-®) 
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This expected net gain is maximized by choosing the terminal decision procedure, 
0 ; if «mom + - Pt) > Him + «<ii(i - n) 
7  ;  i f +  " < o i ( i - P f )  =  +  - P f )  
1  ; i f  « f o o P i + " < o i ( i - p < )  < "noP<+ " < i i ( i - p < ) '  
where 7 is any number in [0,1]. Since it makes no difference to the expected net 
gain, we shall arbitrarily choose 7 = 0. The maximal expected gain of stopping and 
deciding between HQ and is, 
Euj [Ut{i^,ùi.1[{yt))\yt,pt] 
= max{ufQQPi + utQi{l-pi;),UfiQPi + Uiii{l-pt)}, (1.8) 
where E^j denotes the expectation with respect to the measure on 0. defined by the 
posterior probability pf. Should the decisionmaker sample until t = T is reached, 
then a terminal decision must be made. Thus, the expected net gain a.t t = T of a 
decision rule incorporating is 
(1/2^,(1,pt) = Euj [Uj'{u;,A^(yj'))\y'j',pj^j . (1.9) 
At stage t = T — 1, the decisionmaker can either choose between WQ and wj, 
and expect a gain of Euj 1 (^, (z/T—1 1 'P?—l] ' can collect 
> 0 additional observations and expect, for any sequential decision rule d, an 
expected gain of. 
E Ft-I VJ< {Y'J>,D,PJ<)\YJ<_I,PJ<_I,NRP_-^ (1.10) 
and an expected net gain of. 
cj'_l{nrp_l) + TEjp^_J^ Vp (j/y,</,py)br_i,p7^_i,nr_i (1 .11)  
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where Ep^ ^ denotes the expectation with respect to the unconditional cdf of the 
"T—1 observations asked for at < = T — 1. 
Thus, the expected net gain of continuing to sample at < = T — 1 is maximized 
by choosing the sample-size rule defined as: 
= "r-1 ^  argmax { -
ny_i > 0 
^ p r I z / r - 1  ' P T - i ' " r - 1  ) ] } -
Here argmaxJ^•^Q {•} denotes the value(s) of the argument n that achieves a maxi­
mum for the expression in braces. Consequently, the expected net gain at f = T — 1 
is maximized by choosing the stopping rule, 
Sx-iiVT-l) 
0; if Euj 
+ l^T PT)\yT-i'pr-1 ' ^ r-1 
1; otherwise, 
and the maximal expected net gain is, 
VT- 1 PT-1 ) 
= max{Eu} [Uj<_i{u,A^_-^{yj^_i))\yj^_i,p'j^_i] , 
+ d,PT)\yT-hPT-l > )• 
In summary, backward induction yields the following sequential decision rule, 
d* = (5*,^*,A*): 
= 
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(a) A* = {A|}^Q, where 
A * /  N  I® '^^HooPt + mii^-Pt)^moPt + Hni^-Pt) A<(î/^) = < (1-12) 
[ 1 ; if mOPt + «<Ol(l - Pt) < HlOPt + "<ll(l - Pt)i 
(b) = where 
**(y<) e argmax - c(n^) + } 
; < = 0,• • • ,r — 1, 
and 
^r(fr) = 0. (1 13) 
Recall that Ejp^ denotes the expectation with respect to the unconditional cumulative 
distribution function of the observations collected at stage t, defined by (1.5). 
(c) 5* = where 
0; iîrnax{uiQQPt + UiQiil-pt),utiQPt + utii{l - pt)} 
< -ci^'^{yt)) + TEp^ (%+l, )|Pf, (%)) 
1; otherwise, 
and 
S^iVT) — 1" (1-14) 




= max{Ecj ]pi{u},ù,f{yi))\p^ , 
-<#(!/<)) + [Vi+i(yf+i,<i*,pf+i)|p<,^<(2/i)]} 
; i = 0, **-,r — 1, 
V^{yrp,d*,p'j;<) = Eoj [l!7r(w, Ay(yy))|py]. 
1.4 Properties of the Optimal Decision Rule 
The important result of this section is that for any ^ G {0, • • •, T — 1} there exists 
a set of data-independent probabilities that completely define the optimal decision rule 
(Cressie and Morgan, 1989b). 
Definition 1.9 Letpi be the value of p^ for which, 
HooPt + - Pt) = mOPt + Hlli^-Pt)- (1-15) 
As a.consequence of this definition, it is easy to show that, for 1 < T < oo, 
Pi = —r; t = 0,---,T. (1.16) 
("<11 - "<01 ) + ("too - 10 ) 
Definition 1.10 The smallest value of pf G [0,1] for which 
max {u^OOPf + "<Ol(l -Pt)'"<10P< + "fll(l -P<)} 
= -c(t^(î/f)) + r£;jr^ [^1 (%+l ' m+1 ) 1%, (%)] '  
is denoted as p^£ . The largest point pi G [0,1] such that this equality holds is denoted 
as pJjj . Ift = T, then define =p^ = p'^jj-
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The values and partition [0,1] into three intervals: an interval [p^, 1] where 
WQ is chosen, an interval [0,p^] where is chosen, and an interval where 
sampling is continued. The continue-sampling interval (P^,P^) is further divided 
into subintervals over which particular sample sizes are optimal. These results have 
been noted by Ehrenfeld (1972) and proved by Spahn and Ehrenfeld (1974) for the 
special case T = oo, r = 1, time-invariant gains with = "<01 = 0, and time-
invariant costs. 
Formulas (1.12), (1.13), and (1.14) show that the elementary components Sf{yt), 
^^(y^), A|(j/^) of d* and the maximum-expected-net-gain functions V^{yi;,d*,pf) 
depend on the data only through pf. Therefore, from now oh, denote these as 
S^{pt), tpfipt)^ A^(p() and V^{pt,d*), or {pt). The following three lemmas 
present results for the optimal decision rule d* (Cressie and Morgan, 1989b). 
Lemma 1.1 Given 1 < T < oo and t € {0, • • •, T — 1} , vf {pi,d*) is a convex and 
continuous function ofpi 6 [0,1]. 
Lemma 1.2 Given t E { 0 , 1 }  and pf 6 [0,1], V^(pi,d*) is a monotonia 
increasing function of T. 
Lemma 1.3 The sequence of functions uniformly convergent to Vf°, 
V< > 0. 
Recall the definition of pi given by (1.16). The major significance of pi in the following 
two theorems is that pf locates the smallest possible expected value of stopping 
sampling at stage t, i.e., 
HOOPt + HOli^ - Pt) = + ^ tlli^ - Pt) 
= min maa:{ui00P< + "<0l(l-P<)'"fl0P< + "ni(l-P<)}- (1-17) 
P(E[0,1] 
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Theorem 1.1 For given 1 < T < oo and < e {0, • • •, T — 1}, if 
- ci'^tiPt)) + '^^Ft > HIQH + %l(l -%), (1-18) 
then there exist € [0,1] such that pJ'j^ < Pt < pJu the maximum-
expected-net-gain (optimal) decision rule d* is : 
stop sampling and choose u>i , if Pt ^ 
defer a terminal decision and collect f l . l 9 )  
i})f{pt) further observations , if pt G {PtL^Ptij) 
stop sampling and choose WQ , ifpt^ [p^, 1]. 
For a proof of this result, see Cressie and Morgan (1989b). 
By convention, put = pj» = p^jj- Whenever the inequality condition (1.18) 
fails to hold there is no value of pf for which samphng is the best action; the expected 
net gain of stopping exceeds that of continuing for every p( € [0,1], and so p^ and 
PtU exist. 
Note that each {pf^tP^if) pair does not depend upon pf and is therefore not 
data-dependent. This allows the sequence {{PJ^IJIPJI/)}^—Q to be computed before 
any observations are collected. Less obvious is that the sample-size rule |^|'(p^)| 
can also be specified prior to any data being collected. 
Theorem 1.1 could also be expressed equivalently in terms of likelihood ratios 
rather than posterior probabilities. This we do in Section 1.5, where we define the 
VPRT, and in Chapter 2. 
Theorem 1.2 For given t > 0, (pjiipji/) Q (p^\p^^) for every T > t, and 
(p^,p^) converges uniformly to (P^,P^) as T oo. 
A proof of this result is in Cressie and Morgan (1989b). 
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For given t  <  T ,  the continue-sampling intervals { p J j j i P f i j )  widen in a nested 
manner as T increases because the expected net gain of continuing to sample is an 
increasing function of the number of intervals remaining to the truncation stage T. 
Of course, when T = oo and the gain and cost functions are the same at each stage, 
specifically, 
Hij - Hp ^ = 0, " and ctin) = c(n); < = 0, - ,T- 1, (1.20) 
then and = p'^ are independent of t because the passage of time 
does not reduce the number of stages remaining for the decisionmaker. This property 
of time-invariant boundaries for the continue-sampling intervals when T = oo and 
(1.20) holds, is well-known for the special case of the optimal one-at-a-time sequential 
decision procedure (see Ferguson, 1967, pp. 335-356); the difference here is that 
the one-at-a-time procedure's continue-sampling region {p'j^,py) Ç [p^^p'^). The 
containment will be strict in many circumstances. 
1.5 The Variable-Sample-Size Sequential Probability Ratio Test 
This sections extends the pioneering results of Wald and Wolfowitz (1948) and 
Arrow, Blackwell and Girshick (1949) from the class of purely sequential (one-at-a-
time-sampling) decision rules to the much larger class of decision rules described in 
Section 1.4. 
1.5.1 Wide-sense sequential probability ratio tests 
Given T <oo and yf EYf, define the likelihood ratio. 
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and 
Aq = 1. (1.22) 
It follows from (1.4) that, 
Definition 1.11 Let the continue-sampling interval {p^iiPfi/)> defined in Definition 
1.10, be partitioned into rrif subintervals, each with a sample size n-f-j > 0 for j = 
< = 0,• • •,r — 1. Given 1 < T < oo, a wide-sense sequential proba­
b i l i t y  r a t i o  t e s t  f W S F E T J  i s  a  s e q u e n c e  { ( 5 ' ( ,  w h e r e  V ' f ,  
are given by Definitions 1.5,1.4, ^.nd 1.1, respectively, and 
^  =  { ^ 0 '  " ' J  ,  <  =  0 ,  "  ,T  -  1 ,  ( 1 . 2 4 )  
0 < A t  =  P t o < P t l < - - ' <  P t n n  = B t < o o \  i  =  0 ,  •  •  • ,  r  -  1 ,  ( 1 . 2 5 )  
0 < A'j' = Bji < oo; mip = 0, (1.26) 
~ {"fO' " • ' ^ tmt} ' 
n^j > 0 for j = !,• " ^ mf, t = 0,-• • iT — 1, and Nj'= 0. (1.27) 
The associated decision rule is, for yt : 
^tivt) - 1 ^tivt) = 1 , if 0<Xt^^t 
Si{yi) = 0 and collect : 
Mvt) = Hj observations , if PtJ-1 < Af < Pfj (1.28) 
forj e {1, -,m( - 1}, 
'^tivt) = Hmt ezfro observations , if Pt^rnf-l <h< ^ tm^ 
Stivt) =  1 = 0  , if Bi < Xf < oo\ 
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t = 0, - • • ,T — 1. For t = T, 
Sj<{-) = 1, with 
I 1 î/ 0 < Aji < Aj< = Bj> 
Aytojt) - < (1.29) 
0 otherwise. 
Let W C D denote the class of wide-sense sequential probability ratio tests. Obvi­
ously, the usual one-at-a-time sequential probability ratio tests belong to W, as do 
the group-sequential procedures. Less obviously, the Neyman-Pearson test (Neyman 
and Pearson, 1933) based on a fixed sample size, and the two-stage tests defined by 
likelihood-ratio test statistics, belong to W. Thé class W is very broad. 
Due to Wald and Wolfowitz's (1948) optimality result for the SPRT, we use it 
as the "yardstick" against which to measure the performance of any member of W. It 
has been shown by Cressie and Morgan (1989a) that the maximum-expected-net-gain 
decision rule d* described in Section 1.5.2 is contained in W, and hence it dominates 
every member of W, including the SPRT. 
1.5.2 The VPRT 
rp rp 
At any stage t Ç. {0, • • • ,r — 1} the continue-sampling interval of the 
VPRT, defined in Definition 1.10, may be partitioned as, 
where = p*Q < < = pjfj' On these intervals, 
' Pi ^ j = 1, 
V'f iPt) = _ _ * , 
(p&.pn) u - u u (1.30) 
•, m| - 1 
(1.31) 
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where ^ n^2 f "*3, ' 7^ ^t,mt*' ^ € {0, • • • ,7-1} 
the optimal sample-size rule is piecewise constant on (P^>P^) ^.nd there are 
such changes in the value of the sample-size rule. Define 
= (1- ; j = 0, • • •,m?, < = 0, • • • ,r - 1. (1.32) 
and y4| = 5* = Further, define 
From Theorem 1.1, the optimal (expected-net-gain-maximizing) decision at stage t 
is to choose WQ iff G [p^, 1], which, by (1.32), is equivalent to: 
(l-Pj^)PO 
Similarly, it is optimal to: 
& 
( l - P f i ) P O  
It is hkewise optimal to: 
choose WQ iff Xt > < = 0, • • •, r - 1. (1.34) 
choose wj iff y s f = 0, • • •, T — 1. (1.35) 
collect n^j =T}f{\i) observations if PfJ—l J = 1, ' " — 1 
collect (A^) observations if (1.36) 
< = 0, • • •, T — 1. And for t = T,it is optimal to: 
choose wi if X-v < Am = Bm = otherwise choose wn. (1.37) 
^  ^  ( i - p r ) p o  
Therefore, the optimal decision rule d* can be rewritten as a WSPRT: 
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Lemma 1.4 Given T G the variable-sample-size sequential probability 
ratio test (VPRT) is a sequence {("S"*,?/*, where S* and A* are 
defined by (1.14) (1-12); vt defined by (1.33); P* = m| 
and P^j are defined by (1.30) and (1.32); and defined by 
(1.31). 
This result was proved by Cressie and Morgan (1989b). They used, in their 
proof, results on optimal search due to Morgan (1983) and Morgan and Manning 
(1985). Since the gains and cost functions of the VPRT may be time-dependent, 
the components (Sf , P^, N^) of the VPRT are time-dependent even in the 
limiting case of T = oo; (5^, 7/^, A*, Pf,N^) are time-invariant if T = oo and (1.20) 
holds. However, even in this special case, the VPRT is more general than a group-
sequential procedure since, at any stage t, 7/*(Af) is not necessarily a constant for 
every 
Since W C D, where W is the class of WSPRTs as defined in Section 1.5.1, 
and since the VPRT is an element of W, it follows that the VPRT maximizes the 
expected-net-gain over all WSPRTs. 
1.6 Power and Level Considerations 
In this section, we develop theory necessary to compute the type-1 error a and 
the power TT. At each stage t there is a probability of accepting the hypothesis 
. . T* that (JO = uji when the true parameter is w. We shall call this probability (w). 
At the planning stage < = 0 this probability is one if we reject the null hypothesis 
immediately. It is zero if we either take a sample or accept the null hypothesis 
immediately, in accordance with (1.19). 
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Definition 1.12 For a given truncation time T, and for < = 0,1, • • • ,r, define 
a j  ( w )  =  
Pr {Accept wj at stage <|w) 
0 
1 
i f t > l  
if t = 0 and pQ > p^^. (1.38) 
if t = 0 and pQ < 
Then, 
and 
«0 (^) = f Ag < P o x ( ^ - P o ) |  
(i-Poi)^o 
w (1.39) 
of (t*^) = Pr 
ij=0 l(l-P?f,)!'0 (I-PS/)POJ •x)P0 ' 1  PW  
(1.40) 
This is the joint probability that the accumulating Hkelihood ratio passes through 
'continue-sampling' gates at all stages prior to the t-th. At the t-th stage it will cross 
the critical point boundary such that the null hypothesis is rejected, when w is the 
true state of nature. 
Definition 1.13 For a given truncation time T, and for t = 0,1, - • • ,T, define 
(w) = Pr {Accept wjai stage t or sooner\iij) 
Note that, 
Then, 
«0 W = 
T ^ 
aj (w) = ^ fr(Accept u>i at stage i|u>) 
i=0 







Hence, the level and power of a decision rule are, respectively, 
a = a^{uQ) (1.44) 
and 
TT = a^(w2). (1.45) 
Recall from Definition 1.10 that PQJ^ is the lower critical point of the continue-
sampling region. For the VPRT given in Section 1.5, and for w G {WQ,W2}, we 
have by (1.40) and (1.43) that, 
V I^-PWPO 
where = ^  = Note that since Ag = 1 by (1.22), then the first summand 
is 0 or 1. If it is 1 then all of the other summands are 0, since then we do not sample. 
Note also that, 
a f  { u } )  =  a [ [ u )  -  a [ _ i { u } y ,  < = l,---,r. (1.47) 
We will henceforth suppress the superscript T on aj'(w) and aj^(w) for notational 
convenience. We will also suppress the argument w to simplify presentation, with 
w = WQ being understood (unless otherwise specified). 
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1.7 Further Properties 
1.7.1 Invariance property 
Let /qj/i, and g be densities, and let WQ,W2 6 Let /o(®) = g{x — wg), and 
= g{x — wj). That is, the densities /o,/i are members of a location family of 
densities, indexed by w € %, with §{•) corresponding to w = 0. Let 
Fm{x) = P0-^0(®) + (1 - Po)^lW (1-48) 
be a cdf, with density fm{-)i where'm' stands for 'marginal'. 
We have the need to consider the expectation, 
[^/(PI)IPO'"O] ' 
for testing different pairs of simple hypotheses. We therefore introduce the 
notation, 
to emphasize the hypotheses being tested. 
Proposition 1.1 The gain function VQI(PO) hypotheses, 
: w = WQ, versus Hi : w = , 
is the same as for the hypotheses, 
HQIU = 0, versus H[ : U = UI — UQ. 
Proof: It will suffice to show that, for any fixed np > 0, 
^FQ [^/(pi)IP0'"0'(^0'^I)] = W (Pl)IP0'"0'(-^0'M )l • 
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We have that (Pl ) |P01 ^ 0* (^0) )] equal to 
Jmax{«00Pl + W0l(l -Pl)>«10Pl + "ll(l -Pl)}<^-Pm(®) 
= j max{uQQPQfQ{x) + UQlil - PQ)fl{x), 
«ioPo/o(®) + "ii(i-Po)/i(®)}^®' 
suppressing the time index't' from for notational convenience. The first equahty 
follows from (1.8) and (1.9). The second follows from (1.4) and (1.5). By transforming 
with J/ = a: — WQ, we obtain, 
J max{uQQPQfQ{y + wq) + uqi (1 - P o ) f i  {y + wq), 
n o p o f o i y + ^o) +  "11 (1 -  P o ) f i i y + < ^ o ) } ( ^ y  
= jmoa;{uQQPo^(!/ + WQ -wo) + UQi(l -po)^f(T/ + WQ -wi), 
"ioPofl'(f + '^0 - '^o) + "ii(i - Po)9{y + (^0 -
= Jmax{uQQPQg{y) + uoi(l - po)g{y - (wj - wq)), 
u i O P O d i y )  + "ll(l - P o ) 9 i y  -  Wl - wo))}(fy. (1.49) 
By letting, 
9 m { y )  =  P 0 9 { y )  + (1 - P o ) 9 { y  - - wq)), (1.50) 
with cdf Gm{y) and 
p. = podjy) , (1.51) 
P09{y) + (1 - Po)9iy - (wi - WQ)) 
we have that (1.49) is equal to 
y maa:{aoOPl +"Ol(l +"11(1 -Pl)}<'Gm(!/) 
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1.7.2 Symmetry property 
Suppose that we have a location family where fi{x) = g{x — w^), as 
before. Suppose further, that these densities are symmetric. That is, g{-) is an even 
function. If uqo ~ "11 "10 ~ "01 > then we have the following result. 
Proposition 1.2 Let ® location family of densities. Let fi{x) = g{x—u){) 
be symmetric about w^, V w^; i = 1,2 . Then, 
^o(Po) = ^o(l-Po)- (1-52) 
That is, VQ(PQ) is symmetric about pQ = 
Proof: It will suffice to show that, for a fixed value ng > 0, 
\yi{Pi)\po^"ol = [^I^(PI)|I-PO,"o]• (1-53) 
Since we have a location-invariant family. Proposition 1.1 says that without loss of 
generality we can consider the hypotheses, 
HQ : w = 0, versus HI : w = . 
The quantity [^(Pl)|PO)"o] equal to 
J max{uQQPQg{x) + uoi(l - Po)gix - wj), 
"01WW + "11(1 - P0)9ix - u}l)}dx. 
By transforming with y = —x -f wj, we have that this integral is equal to 
jmax{uQQPQg{-y -f wj) -f uqiCI - Po)9{-y), 
"oiPoK-y + ^ i) + "ii(i - Po)9{-y)}dy-
42 
By symmetry about 0 of the density g{-), we have that this integral is equal to, 
J m a x { u i i { i  - P Q ) g { y )  +  U Q i P Q g i y  
"10(1 - pok(y) + «00P05'(f -
= Jmax{uoo(l - Po)9iy) + UQip^giy - w^), 
«io(i - PoMf) + ^ iiPodiy -
The last equality follows since uqo = "H and uqj = ujg- Recall from Proposition 
1.1 the definition of gm and Gm- Then the last integral above is equal to 
jTnaa;{uooPl 4  ^ Ol(l  -Pl) ,"10Pl + "ll( l  — Pl)}dGmiy) 
= ~P0'"0] • 
Hence, (1.53) holds. Therefore, (1.52) holds. O 
It can be shown that the results above also hold for location families of probability 
mass functions. 
Corollary 1.1 Suppose the assumptions of Proposition 1.2 hold. Let 
Hq : w = WQ, Hi : u) = u)i, 
and 
HQ ; U; = , H^ : U> = UQ. 
Then, VqI(po) is the same for both pairs of hypotheses. That is, VQ(PQ) is symmetric 
in the parameters {WQ,W2}. 
Proof: For the hypotheses {HQ^H\), we have that 
^(po) = - p q ) -
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The right-hand side can be interpreted as the expected net gain for the prior pg = 
1—PQ = fr(w = wj). Then, Vq^(1 — pg) is the expected net gain for The 
result follows. O 
1.8 Summary of the Other Chapters 
Chapter 2 is a numerical presentation of the VPRT assuming a Gaussian model, 
which is perhaps the most relevant model for clinical trials applications. In Chapter 3 
we shall examine a Bayesian sequential procedure developed by Berry and Ho (1988), 
which has similarities to group-sequential procedures; VPRT-like versions will be 
developed. 
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2. TESTING THE MEAN FROM A GAUSSIAN DISTRIBUTION 
USING THE VPRT 
2.1 Introduction 
In this chapter we present distribution theory and examples in which the VPRT 
could be useful and desirable to use in practice. In order to show examples similar 
to those that might be commonly seen, e.g., applications to sequential clinical tri­
als, we consider a Gaussian model. It is well-known that the sample mean is often 
acceptably close to Gaussian for moderate sample sizes (by the Central Limit Theo­
rem, e.g., Chung, 1974, p. 205). Distributions for which the Gaussian distribution is 
a reasonably close approximation include those that are continuous, unimodal, not 
badly skewed, and have moderate-length tails. This often includes continuous phe­
nomena that are nonnegative, such as height and weight. It also includes discrete 
random variables that are approximately symmetric. Even for badly skewed data 
there is often a variance-stabilizing transformation yielding nearly Gaussian data in 
a different scale. 
Those who prefer procedures based on the frequentist criteria of probabilities 
of type-1 and type-2 errors are often reluctant to consider Bayesian methods. They 
believe that Bayes-optimal procedures often correspond to unacceptably large type-1 
errors and low power. In some applications the total "value" or (negative) risk of 
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the decision procedure is more important than probabilities of error types. It is of 
interest to consider such procedures and calculate their probability of type-1 error (a) 
and their power (TT), and, conversely, to consider the implications that specification 
of a and TT has on the gain and cost parameters of the decision procedura. 
As we have seen in Chapter 1 in (1.3), u-^j is defined to be the gain at stage t 
for choosing state i when state j is true. In the terminology of Chapter 1, we seek to 
understand the relationships among the VPRT parameters pQ, c(-), r, and 
how they are related to a and TT. Analytical results are not easily obtained, due to 
the complexity of the expected net gain function (PQ)- However, much insight 
can be gained by looking at examples and exact computation of a and TT. 
2.2 Notation 
Let j = 1,• • • ,m^ be a doubly-indexed family of sample sizes based on 
some sample size rule, as described in Section 1.5. It is a set of alternative sample 
sizes requested at stage t and obtained at stage i +1; for i = 0,1, • • •. Let Xfj be the 
random variable of the j-th observation requested at stage t, and obtained at stage 
< -f 1 for J = 1, • • • — 1. We shall consider first = 1, Vf. That is, at each stage 
the sample size taken is > 0. Let 
= 0, Vj. 
Let 
m 
Xt+ = E Xtj, (2.1) 
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and, when > 0, 
X i j ^  =  - — <  =  0 , 1 ,  -  - .  ( 2 . 2 )  
"<1 
These are, respectively, the sample sum and sample mean of observations requested 
at stage t, and obtained at stage < + 1. Let 
Foj = 0;Vj, (2.3) 
= ^0;"; i = !'•••'"Ob (2.4) 
~ ^ (2-5) 
Note that the k-th random variable obtained since the planning stage of the 
sequential procedure. Let 
n+ = (2.6) 
3 
Fi+ = (2.7) 
E ^ ii 
2=0 
These are, respectively, the accumulated sum and the accumulated sample mean at 
stage t. Note that 




t — 1 
= E *;+• (2-9) 
2=0 
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2.3 Theoretical Results 
Although the procedures presented in this chapter are based on Bayes gains, we 
are also interested in finding the sequential tail probabilities of these procedures, i.e., 
the probabilities that the sequence of accumulating sample means stays within a given 
set of boundaries at stages 1, • • •, T — 1. Let Gau{fi, be notation for a Gaussian 
distribution with mean fi and variance cr^. Let and $(•) be, respectively, the den­
sity and cumulative distribution function (cdf) of the standard Gaussian distribution 
Gau{0,1). We have the following result. 
Proposition 2.1 Let 
X f j  ~  i i d  G a u { i i , ( T ^ ) ,  
where Xfj is requested at stage t and obtained at stage <  +  1 ;  j — 1 ,  •  •  • ,  t = 
0,1, ' - . Let and $(•) be, respectively, the density and cumulative distribution 
function of the standard Gaussian distribution Gau(0,1). Then, for a given set of 
constants Aj < 5^, (i = 1,• • • ,<), 
P \Ai < < Bi,A2 < ^ 2+ < < Y-t^ < Bt\ij\ 
.^11 -1/2 (uQi -hnuhngl^ZQ 
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/ \ ' A=0 fc=0 MÉ - H - E -lN \ ' t=0 6=0 • 
/ \ / t=n t=:n 
«*-2,1 
<—2 i—3 I jn 
L k 0 k 0 
t — 2  t — Z  2 / g  
"jfcl - E ^61 
&=0 6=0 
0 ( , - . , -"j(î^); | . . . -g.ff , ))  
. (• . -u-»{(^) | .M-g.;f- . ))  
<f>{zt-2) dzt-2 • • • 9^(^o) (^^0- (2-10) 
Proof : The probability 
P \AI < Yi^ < < YtJ^ < Bt\ii\, (2.11) 
can be written aa 
n (4 < 5';+ < Bj}\f (2.12) 
This probability is conditional on /x, the true mean, but we will suppress this condi­










t ( j-1 i-1 
n  m  - ^ j - i , +  <  ^ j +  - z  " i l  - ^ i - i , +  j=l z=0 i=0 
j—1 j—2 j—1 j—2 
JL ^il - IZ ^i+ < ^ j-l,+ < .13 "zl - Z ^i+ 1(2-13) 
< 
n 
17=1 %=0 2=0 * 2=0 i=0 
The last equality follows from (2.3),(2.4),(2.9) and (2.8). Expression (2.13) is equal 
to 

























«g, .-?, .  (5^) ]. (2.14) 
M - , 1/2 _ 
= — {^i+ - ~ ii(f Gow(0,1), for i = 0,• • • — 1. 
Then (2.14) is equal to 










\ ^ / 2=0 2=0 
By conditioning on ZQ,- • •, ZF_2, and noting that P (^/_i < x) = $(a:), we obtain 
(2.10). • 
We would like to find the joint probability that a random walk of the sequence 
of accumulating sample means arrives at stage t and exceeds a given boundary 
point at that stage. To find sequential tail probabilities such as these, we need to 
evaluate, for example, expressions of the form: 
P [AI < YI^ < < oo]. 
This is the probability that the moving sample mean stays between a given pair of 
bounds at stage 2 = !,•••,< — 1, but exceeds a given bound at stage t. We have 
the following result. 
Corollary 2.1 Let 
X i j i i d  G a u { f i , c r ^ ) ,  
where Xfj is requested at stage t and obtained at stage ( + 1; j = 1, ' 
Z+U{0}. Then, 
P[AI<YIJ^< Bi,---,At_I < Yi_i J^ < Bt_I,Bt < < oo] 
r"01~^^^[(^^ï^)"0l] 
,"(i; ^ G 
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(^'"'"J"^) E "jkl - Ë 
L\ / A:=0 &=0 
1-1  / 




A ' k=0 k=0 
\ / jt.=n fc=n A:=0 
t—1 t—2 
m - E "If &=0 
Proof: In (2.10), let = Bf and Bf = oo. 
(2-15) 
• 
2.3.1 The WSPRT 
Suppose that we wish to test sequentially the simple hypotheses 
Hq : N = HQ, versus : // = /xj, 
based on data distributed according to a Gau{iJ,,(X^) distribution, where cr^ is a 
known positive constant. To perform this test, we shall consider the class of wide-
sense sequential probability ratio tests (WSPRTs), as described in Section 1.5.1, and 
in particular the VPRT, as described in Section 1.5.2. 
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(2.17) 
Let T G where T is the truncation time. We have seen in (1.30) and (1.31), 
a definition of optimal sample sizes corresponding to optimal continue-sampling in­
tervals. Similar definitions for their suboptimal counterparts will be given here. 
Consider the (perhaps suboptimal) continue-sampling intervals for i = 0, • • •, T* — 1: 
U • • • U {p'tjrrn—2'>p't,mt—l^ ^ (2.16) 
Suppose that we sample (perhaps suboptimally) 
; Pt G and j = 1, • • • ,mi - 1 
^Truf ' Pt ^ ^Pt,mf—VPt,mj)'' 
where nj-^ ^ V'i(-) is a sample size rule 
given in Definition 1.4. That is, we have a continue-sampling interval 
defined in Definition 1.10 and for f e {0, • • • ,2" — 1} the sample-size rule is piecewise 
constant on where there are such changes in the value of this rule. 
We note in passing that these sample sizes and corresponding continue-sampling 
intervals can be chosen in an optimal manner, as prescribed in the formulation of 
the VPRT. We shall also consider the expected net gains using a sample of size just 
one (in the continue-sampling region of the VPRT) and compare these to those using 
the optimal sample sizes for the VPRT formulation. The resulting procedure is 
called a truncated sequential probability ratio test (or TPRT). Of course, the TPRT 
procedure has a single continue-sampling interval (P^iP^)» but we can still compare 
the expected net gains of the two procedures for fixed values of pQ. We reiterate that 
the purpose of considering > 1 and partitioning the continue-sampling interval, 
as described above, is to find that particular set of Bayes-optimal sample sizes and 




_ . _ 
(1 -Ptj)PO 
; j = 0, • • •, m^, < = 0, • • •, r - 1. (2.18) 
Let us consider first = l,Vi. We will suppress hereafter the superscript T on P^, 
pjj, and njj for notational convenience, noting once and for all that these quantities 
are functions of T. Suppose that the sequence pg, " • ,Pt traverses a path to stage t 
such that POO < PO — ^01' ' ' ' ^ PtO < Pf ^ Ptl^ where we sample observations at 
stage i for i = 0, — 1. We wish to know the probability of this event. Let 
and 
- - f ' o  +  n  (2.19) 
= 
- ^1 - f o  
a = fiQ 
if ^ ' 
(2.20) 
We have the following result. 
Proposition 2.2 Let 
X^j ~ iid Gau{fi,cr ), 
where Xfj is requested at stage t and obtained at stage < + 1; j = 1, 
Assume, without loss of generality, that 
>^tV ;  t e z + .  
n > f^o- (2.21) 
Ifmt = 1, Vi, and pQO < PO ^ POl' 
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•P[P10 < PI <P11'P20 <P2 < P 2 h ' " ^ P t O  < P t  < P t l \lA 
«01 [i"oi -
#«01-/ÏÏ^'"(A0)] 
( P u ) ]  





' s,"" " '" 
I 
"<-2,1 -1/2 
-w t—2 (-3 
, - 1 / 2  
"<-2,1 
^ (T , ^ t n  \  ^ 1/2 
t=0 
or k=0 




t-2 7 , /» \ 1/2 
;E "H - -Z-—Z M,l) - Z "61 k=Q 
•<f>{zt-2) ^ H-2 • • • ^(^o) «'^0-(2-22) 
Proof : For a nonsequential sample Zi, • • •, Zn of size n from a Gaussian distribution, 
the likelihood ratio is 
'« • S 
= exp ^(mi -/io)(M - ^ )] (2.23) 
55 
At stage i, 
PiO < n ^  Pil 
is equivalent to 
^0 ^ ^  (^z+) — ^ih 
by (1.4),(2,18), and (2.23). This is equivalent to, 
i-l 
E "ifcl _ 
(A-,O) < (/'I - ^o)(7^ - n+) < (A-,I) , 
which in turn is equivalent to, 
F- <F.+ < K- , Vi 6 ZH-. 
in-H) E "H (/^i - MO) Z "61 
t=0 6=0 
Therefore, 
f  [ P I O  < P l  < P l l > P 2 Q  <  P 2  <  P 2 h "  •  ^ P t Q  < P t  < P t l \ l A  
- ^ [^1 < ^1+ < -®1)^2 < ^2+ < ^2) 
where 
^ p—'''"Ki) . 
' 2 — 1 
(/^i - /^o) Z "61 
6=0 
and 
B: = 11- i - l  
(/'I -/^O) E "61 
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We see by (2.15) that the index i of Yon the left-hand side corresponds to the 
(i — l)-th integral on the right-hand side. The upper bound of integration of the 
[i — l)-th integral in (2.15) is 
t-1 i-2 
n. z—1,1 
-1/2 MÉ V 1 /2 "tl - E k=0 k=0 
Substituting (2.25) into this expression we obtain as the upper bound of integration 
of the (i — l)-th integral in (2.10), the expression 
( \ 
"z-1,1 
-1/2 f ^ - i-1 





which is equal to 
"2-1,1 
-1/2 (T , /n \ 1/2 
by (2.20). The corresponding lower bound follows similarly. Hence, the result (2.22) 
follows. O 
The following result gives the joint probability that the sequence , • • •, Pf stays 
bounded at stages i = 1, - - — 1, and drops below a given bound at the t-th stage. 
This is the joint probability that HQ is rejected at the t-th stage and no sooner. 
Corollary 2.2 
f [PlO <Pl <PlhP20 <P2 < P21' " ,0 < Pf <Pm] 















(^-i,o) - E 
z, n 
"1-2,r'-'^ 





; E "TL - (^<,O) - E 
6=0 
'(f>{zt-2) ^ H-2 • • • <?i(^o)<^^0-(2-26) 
Proof: In (2.22), let p^Q = 0 and pn = PiQ. O 
Sequential tail probabilities yield joint probabilities of arriving at a certain stage, 
say the t-th stage, and rejecting HQ at that stage. This corresponds to an accumu­
lating sample mean passing through continue-sampling gates (pairs of critical points) 
at all stages but the t-th stage, at which time the sample mean passes into the 'tail' 
of the distribution, to the right of the upper continue-sampling critical point. A tail 
probability is, for us, the probability of such an event. 
For the special case Z" = 1, we can obtain the tail probabilities for arriving at 
stage 1 (i.e., taking a sample at stage 0) and rejecting HQ, assuming either HQ or 
Hi is true (corresponding to a-level or power, respectively). We can do this for a 
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given sample size ngi» without the need to find Pq j ^ = pgO' where was defined 
in Section 1.4. For this simple case, we can obtain a solution without the need for 
numerical integration or root-finding for This probability is 
«1 (P0'A') = -P[P1 ' 
as we have seen in Definition 1.12. We have the following results. 
Corollary 2.3 Assume the truncation time T = 1. Then, 
<•} (%,") = 1 - * ( 
Proof: At < = 1, we choose HQ if, 
"111 -"101 . 1 -
«100 -"110 Tf))] .(2.27) 
"lOOPl +"10l(l - Pi) > "llOPl + "lll(l - Pi)' (2.28) 
as we have seen in (1.7). We choose H\ otherwise. The break-even value of pi at 
which we have equahty in (2.28) is, 
P. = %i - "mi , 
"mo - "mi +"<11 -"f 10 
as we have seen in (1,16). Then, 
«1 (P0'^) = -f [P1 <PllH ' 
= f [0 <Pi <PiW, 
by Definitions (1.9) and (1.10). 
By Corollary 2.2, with < = 1, we have that 
<A (PO'/^) = 1 -  ^  ' -1/2 r^inoi Ttni \ 01 1 H - c o  In (Âi)};  (2.29) 
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Furthermore, 
P l i  =  "111 -"101 
"100 -"101 +"111 -"110 
as we have seen in (1.16). Therefore, 
p ^ Pii(i-Po) 
( l-Pll)PO 
^ "111 -"101 , 1 -PO . 
"100-"110 PO 
Substituting this into (2.29), we obtain (2.27). • 
Corollary 2.4 If cr^ = 1, «M = and ITJOL = 0 = «HQJ 
ai(PO'/^) = l-^ n -1/2 j;;. 1 01 1 ^ "01 - %— In 
n - f ^ Q  (^))] 
=  1 — 0  
- m) ^ (r )^ ^"01 1/2 
Proof: This follows from Corollary 2.3. 
Proposition 2.1 gives an expression for. 
• 
P \Ai < Yi^ < BI,A2 < ^ 2+ < < Bt\n\ , 
with |yl^, in the same scale as the data. We can also express the same probability 
in terms of {pfOiPtl}» assuming the sample size rule (2.17), for = 1, = 0,1, • • •. 
Proposition 2.3 Let 
X^j ~ lid Gau{n,cr)^ 
where X^j is the random variable of data requested at stage t and obtained at stage 
t 1; j = 1, - '  ' t = 0,1, ' -. Suppose the constants < B^, i E are 
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given. Let rrif = 1, Vi = 0,1, • • •. If PQQ < PQ — PQl' 
P [ A i < Y I ^ <  B i , A 2  <  ^ 2+ < < Bt\fi] 
=  P { P 1 0  < P 1  < P n ^ P 2 0  < P 2  <  P 2 h ' "  i P t O  <  P t  < P t l \ f A ^  (2 30) 
where we sample according to the rule (2.17), and fori > 1, 
z-1 
E "61 




«2 ~ ^"^2—(/'I •"/^0)(^~ AO-
Proof : By (2.24), we have 
Ai = ]! 
This implies that. 
(AM) .  
2 -1  
i n - f ^ o )  E "61 
6=0 
2 - 1  
/n Kl) = (/: - 4) E "61 
^ 6=0 
and, equivalently, that. 










E  H i  
This in turn implies that, 
M i + 
by (2.18). Similarly, we obtain (2.31) and (2.32), O 
2.3.2 Partitioning {pfitpfy) 
The critical points defining the continue-sampling interval were given 
in Definition 1.10. Now consider the general case, where we have parti­
tioned into subintervals as in (2.16). We have seen that, 
Of (po> t^) = f [Reject ^0 or before stage tj/x]. (2.35) 
This is the type-1 error (a-level) if i = T and fi = //Q, and the power if fi = fii. We 
have also seen that, 
rp 
dQ (pQ,/z) = 0 or 1, depending on pg (2.36) 
and that, 
~"£-l(PO'^)'^ = 1," ' - (2.37) 
by Definition (1.12). This is the probability of arriving at stage t and rejecting HQ 
at that stage. Hence, 
^^ïiPO:M)i t = 0,---,T. ^ (2.38) 
i=0 
62 
Suppose, in accordance with (2.16) and (2.17), that the value of pQ lies in a subset 
of the continue-sampling region, 
P0J-1<P0^P0J, (2.39) 
with a corresponding sample of size j, obtained at < = 1. We will denote this 
sample size as TÎQ for convenience. 
Proposition 2.4 
«1 (PO'^) = 1 - ^  (2.40) 
This follows from Corollary 2.2 with T = 1. The case T = 1 has also previously been 
proved by Cressie and Morgan (1986a, p. 12). For 1 < ^ < T we have the following. 
Proposition 2.5 Let 
m 
X-f-j ~ iid Gau{fi,a ), 
where X^j is requested at stage t and obtained at stage Z + 1; j = 1, • • • t £ Z'^. 
Assume the sample size rule given in (2.16) and (2.17). Assume, without loss of 
generality, that 
n > PO- (2.41) 
^/POO < PQ — POmg ^tj defined in (2.18) then. 
of (PO'P) 
= z / 
;i=l riQj 
, - 1 /2 
1/2 
"Oil [(T^oji m-fiQ In 
Ki-i)] 
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^ à '" (^'+'*+1 -i)-£ 
mi "<-2j( ^ 
z / 
•" ' ni-2,;j 
2^ f , /n \ V 1/2 
g/% - Ï7^'" k=0 
' - * ("'-ivT'/' [! E"% - '" hjJ - E 
9^(^(-2) (^^<-2 ' ' ' <^(^0) (^^0- (2-42) 
Proof : The equation (2.42) can be written as a sum of integrals by an appropriate 
interchange of summation and integration. The result then follows from Corollary 
2.2. O 
2.4 Numerical Results 
This section presents two numerical examples of some of the theoretical ideas 
shown in the last section. We shall examine the simple null hypothesis Hq : fiQ = 0 
and, except where stated otherwise, the simple alternative hypothesis Hi •. m = 1. 
Recall from (1.3), that u^j is the gain at stage t for choosing state i when state j is 
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true. The main question of interest concerns the effect of the parameters } on the 
expected net gain, and on the type-1 and type-2 errors. We are also interested in what 
effect n-optimization and receding truncation stage T have on these quantities. We 
examine them for T < 5, both for the VPRT and the TPRT (one-at-a-time sampling), 
in the continue-sampling region of the VPRT. Furthermore, we would like to know 
what the effect is of symmetric versus asymmetric gains. In the examples presented, 
we consider only r = 1 (no discounting). Among the many possible cost functions, 
the main one of interest is the simple linear cost function: eg + (cj x ng). We 
shall consider only the cost parameters eg = 0 and cj = 1 (unit cost per observation 
w i t h o u t  s t a r t - u p  c o s t ) .  C l e a r l y ,  w e  c a n  f i x  c \  a t  o n e ,  a n d  a l t e r  t h e  v a l u e s  U f ^ j ,  
without losing the generality of our conclusions about expected net gain. 
2.4.1 Example 1: u^qO = 125, = 75, = 0 = ^<01 
In this section we consider an example with parameters ~ 125, = 75, 
and = 0 = w^Ql* interesting to see an example of the VPRT, with param­
eters Ufj^j not symmetric in the two hypotheses. Figure 2.1 shows, for the TPRT, 
the gain function V(^(pol"0 ~ 1) versus pQ for T <5. We see that the expected net 
gain increases with the number of sampling periods available. Values for this graph 
are given in Table 2.1. We see that for moderate values of pQ there is a substantial 
increase in expected net gain to be had by planning for a two-stage procedure, as 
compared to a one-stage procedure. The marginal advantage, in terms of increased 
expected net gain, for considering T > 2, decreases rapidly as the truncation period 
T increases to 5. That is, one stands to gain considerably by planning for two stages 
instead of one, but planning for more than two stages yields only a small increase in 
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expected net gain. 
The function (PQ), for the VPRT, was also computed for T < 5. A graph 
is presented in Figure 2.2, with values in Table 2.2. Comparing these to Figure 
2.1 and Table 2.1 shows the relative advantage, in terms of expected net gain, of 
optimizing on sample size. By scanning the tables, we see that, for PQ G [.25, .85], a 
slightly larger gain can be obtained by optimizing on sample size when T = I than 
by planning a 5-stage procedure. That is, Vq^Pq) ^ ^(P0l"0 ~ 1) for moderate 
values of PQ. For these moderate values, one can expect to gain shghtly more with a 
non-sequential procedure and n-optimization, than with a 5-stage procedure and unit 
sampling. In general, one might require a total sample size greater than 5 with the 
VPRT and T = 1, but the gain and cost structure is such that this plan is optimal for 
moderate pg- This is perhaps better seen in Figure 2.3, a 3-dimensional graph of both 
VQ (POIJ^O ~ 1) &nd VQ(PQ) versus PQ versus T, for T < 3 and PQ 6 [0,1]. It shows 
that we can expect to gain more, after the first sample is taken, if we have more 
future sampling periods available to us, than if we had only one sampling period. 
Values for this graph are given in Tables 2.1 and 2.2. 
Figure 2.4 is a graph of the optimal sample sizes TIQ versus PQ for the VPRT. 
At the PQ—points where the sample sizes change, the expected net gains are equal 
for these two sample sizes, and both are such that this expected net gain is maximal 
over all possible sample sizes. For small values of pg the optimal sample size is zero, 
indicating that we should accept Hi immediately, without sampling. As pQ increases, 
the optimal sample size jumps from zero to five at pQ = .088. The optimal sample 
size continues to increase with pQ to a maximum of ten, and then it starts decreasing. 
At PQ = .836, the optimal sample size changes from six to zero. This is the upper 
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critical point of the continue-sampling region of the prior. For pQ > .836 it is optimal 
to accept HQ without sampling. Data for this figure are presented in Table 2.3. 
In Figure 2.5 and Table 2.4, we present, for T = 1, the type-1 error versus pg 
for the VPRT and the TPRT. When PQ = 0, the probability that HQ is true is zero. 
Hence, when pQ = 0, we always reject, and the type-1 error is necessarily one with 
either sampling scheme. As pg increases to one, the type-1 error steadily decreases, 
necessarily to a low of zero when pQ = 1. The function appears to be convex in 
the continue-sampling region of pQ for the TPRT, but not for the VPRT. For the 
latter, we see some "saw-teeth" in the function, for moderate values of pQ. This is 
evidently due to abrupt changes in ng, a function of pQ, in Equation (2.27). We note 
however, that the type-1 error, as a function of pQ, is essentially convex for pg in 
the continue-sampling region, for both the VPRT and the TPRT. Also, the type-1 
error for the VPRT is substantially less than that for the TPRT over most of the 
domain. We see from Table 2.4 that, for the VPRT, the type-1 error is less than 
.05 for PQ > .5. For the TPRT, however, the type-1 error is less than .05 only if 
PQ > .65, approximately. If one were to plan a procedure with the VPRT, then the 
type-1 error would be acceptably low for pg G [.5,1]. For the TPRT, on the other 
hand, the type-1 error would be acceptably low for pg E [.65,1]. We see that in this 
example, the VPRT has, in addition to the advantage of maximal expected net gain, 
the extra advantage over the TPRT of yielding an acceptably small type-1 error over 
a larger domain of values of pg. 
We see in Figure 2.6 and Table 2.5 a graph and values of the type-2 error versus 
pg for the TPRT and VPRT. When pg = 0, we always reject HQ, indicating a power 
of one, and equivalently a type-2 error of zero. As pg increases from zero to one, 
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the type-2 error increases from zero to one, as it must. We note at once that the 
type-2 error for the VPRT is less than that for the TPRT over most of the pg-domain. 
Equivalently, the VPRT has power at least as large as that of the TPRT, for any 
fixed value of pg, except for a small range of small values of the prior. Thus, the 
VPRT yields simultaneously a maximal expected net gain, smaller type-1 error and 
larger power than does the TPRT, for most pg G [0,1]. We also observe the same 
saw-tooth phenomenon of the type-2 error as a function of pg, for the VPRT, as for 
the type-1 error. It appears that, for non-sequential sampling, optimizing on sample 
size relative to one-at-a-time sampling has the advantage of yielding a procedure with 
greater power for a given type-1 error. This conclusion holds for most pg € [0,1]. 
Figure 2.7 is a graph of TT (power) versus a (type-1 error) for the VPRT and 
the TPRT. We see that for any value of a the power for the VPRT is greater than 
that for the TPRT. Note in particular that for a = .05 the power for the VPRT 
is about .92 but that for the TPRT is only about .18. Both the type-1 and type-
2 errors were computed as functions of pg, and presented in Tables 2.4 and 2.5, 
respectively. Values for this graph can be inferred from these two tables together, 
since the power is obtained from the type-2 error by subtraction from one. Both IT 
and a are parameterized by pg. 
Figure 2.8 is a graph of (pg |ng = 1) versus /i^, for G [.25,2] and T < 5. 
It was interesting to plot the V-function eis a function of /xj for a fixed value of pg. 
The value pg = pg is one at which both ng > 0 and TIQ > 0, and was used for this 
reason. We note that the expected net gain increases with m for a fixed value of pg, 
and we conjecture that the functions are concave. It is easy to show that as —» oo, 
Pi —» 0, regardless of the values of the data. We note as before that (pqI^O ~ 1) 
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increases with T. Data for this figure are given in Table 2.6. A similar graph for the 
VPRT of Vq^(po) versus for m G [.25,2] and T < 5, is presented in Figure 2.9. 
The functions go up more steeply and then level off more rapidly, as ni increases. 
The V-functions increase with T for any fixed m, as they must. Data for this figure 
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Figure 2.1: VQ^(poI"0 = 1) versus pQ, pQ e [0,1], T <5\ Example 1 
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Table 2.1: {pqItiq = 1) versus pg» PO ^ [0,1], 
r < 5; Example 1 
PO 0.00 0.05 0.10 0.15 0.20 0.25 
1 74.000 70.297 67.000 64.437 62.782 62.011 
2 74.000 70.530 68.102 66.688 66.138 66.306 
3 74.000 70.826 69.112 68.443 68.538 69.230 
4 74.000 71.116 69.948 69.801 70.317 71.341 
5 74.000 71.373 70.628 70.850 71.669 72.921 
PO 0.30 0.35 0.40 0.45 0.50 0.55 
1 62.129 63.054 64.734 67.240 70.340 74.055 
2 67.123 68.512 70.395 72.754 75.543 78.751 
3 70.414 72.034 74.029 76.363 79.051 82.032 
4 72.765 74.528 76.610 78.956 81.576 84.440 
5 74.512 76.386 78.520 80.883 83.462 86.260 
PO 0.60 0.65 0.70 0.75 0.80 0.85 
1 78.265 82.990 88.139 93.621 99.392 105.382 
2 82.368 86.347 90.718 95.446 100.528 105.963 
3 85.341 88.943 92.865 97.116 101.705 106.670 
4 87.564 90.943 94.581 98.508 102.750 107.345 
5 89.260 92.488 95.938 99.638 103.624 107.941 
PO 0.90 0.95 1.00 
1 111.527 117.750 123.999 
2 111.724 117.774 123.999 
3 112.032 117.830 123.999 
4 112.369 117.906 123.999 
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Figure 2.2: (PQ) versus pg, PQ G [0,1], T < 5; Example 1 
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Table 2.2: (pg) versus PQ, PQ G [0,1], T < 5; Example 1 
PO 0.00 0.05 0.10 0.15 0.20 0.25 
1 74.000 70.298 68.455 69.483 71.085 73.024 
2 74.000 71.203 71.132 72.272 73.929 75.861 
3 74.000 71.782 72.075 73.343 75.023 76.974 
4 74.000 72.086 72.543 73.864 75.593 77.543 
5 74.000 72.258 72.796 74.191 75.914 77.891 
PO 0.30 0.35 0.40 0.45 0.50 0.55 
1 75.133 77.330 79.605 82.104 84.603 87.206 
2 77.971 80.219 82.542 84.978 87.502 90.091 
3 79.078 81.322 83.676 86.103 88.619 91.216 
4 79.659 81.918 84.263 86.694 89.214 91.807 
5 80.015 82.252 84.597 87.034 89.552 92.154 
PO 0.60 0.65 0.70 0.75 0.80 0.85 
1 89.831 92.630 95.548 98.547 101.858 105.574 
2 92.759 95.527 98.451 101.468 104.768 108.389 
3 93.887 96.677 99.572 102.611 105.843 109.369 
4 94.488 97.263 100.163 103.182 106.397 109.837 
5 94.845 97.623 100.502 103.529 106.715 110.112 
PO 0.90 0.95 1.00 
1 111.525 117.751 123.999 
2 112.620 117.940 123.999 
3 113.335 118.153 123.999 
4 113.718 118.291 123.999 
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Figure 2.4: Optimal sample sizes UQ and associated continue-sampling intervals 
[PO,i'PO,i+l) for T = l, Example 1 
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Table 2.3: Optimal sample sizes ng and associated continue-sampling intervals 
\PQ,hPO,i+i) for T = 1, Example 1 
Ô 5 6 7 ~8 9 
PO [.000, .088) [.088,.105) [.105, .135) [.135,.192) [.192, .278) [.278, .378) 
raj 10 9 8 7 6 0 
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Figure 2.5: Type-1 error versus pg, TPRT and VPRT; Example 1 
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Table 2.4: Type-1 error versus pQ, TPRT and VPRT; Example 1 
^ ÔÔÔ 005 ÔJÔ Ôl5 020 Os OÔ or 
VPRT 1.000 1.000 0.358 0.195 0.135 0.114 0.083 0.072 
TPRT 1.000 1.000 1.000 0.765 0.646 0.535 0.435 0.348 
PO 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 
VPRT 0.062 0.054 0.047 0.041 0.035 0.030 0.029 0.024 
TPRT 0.273 0.209 0.156 0.113 0.078 0.052 0.032 0.000 
PO 0.80 0.85 0.90 0.95 1.00 
VPRT 0.021 0.000 0.000 0.000 0.000 














Figure 2.6: Type-2 error versus pQi TPRT and VPRT; Example 1 
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Table 2.5: Type-2 error versus pg, TPRT and VPRT; Example 1 
^ Ô3Ô 005 ÔIÔ Ô7Î5 Ô3Ô 025 OÔ 035" 
VPRT 0.000 0.000 0.031 0.037 0.042 0.052 0.053 0.062 
TPRT 0.000 0.000 0.000 0.042 0.085 0.138 0.201 0.271 
PO 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 
VPRT 0.072 0.081 0.092 0.103 0.116 0.131 0.175 0.199 
TPRT 0.347 0.425 0.504 0.584 0.661 0.736 0.805 1.000 
PO 0.80 0.85 0.90 0.95 1.00 
VPRT 0.272 1.000 1.000 1.000 1.000 
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Figure 2.8: (Pol"0 = 1) versus m, m E [.25,2], T < 5; Example 1 
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Table 2.6: {pqIuq = 1) versus m, 
/ZI 6 [.25,2], r< 5; 
Example 1 
n 0.250 0.500 0.750 1.000 
1 50.698 55.290 59.750 64.015 
2 51.791 58.110 64.109 69.586 
3 52.493 60.059 67.056 73.186 
4 52.995 61.548 69.263 75.739 
5 53.375 62.734 70.988 77.635 
^1 1.250 1.500 1.750 2.000 
1 67.991 71.728 75.028 78.096 
2 74.432 78.587 82.046 84.841 
3 78.307 82.393 85.517 87.816 
4 80.863 84.684 87.392 89.227 
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Figure 2.9: Vq (PQ) versus m, m 6 [.25,2], T* < 5; Example 1 
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Table 2.7: (PQ) versus g [.25,2], 
T < 5; Example 1 
Ml 0.250 0.500 0.750 1.000 
1 52.331 63.920 72.964 78.652 
2 53.344 66.499 76.028 81.599 
3 53.822 67.699 77.326 82.725 
4 54.133 68.422 78.035 83.316 
5 54.333 68.885 78.475 83.648 
/'l 1.250 1.500 1.750 2.000 
1 82.415 84.890 86.648 87.863 
2 84.960 87.112 88,550 89.555 
3 85.885 87.882 89.179 90.133 
4 86.358 88.229 89.508 90.354 
6 86.620 88.455 89.657 90.460 
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2.4.2 Example 2; u^qO ~ 100 = «fn» u^iQ = 0 = u^qI 
In this section, we examine an example that is symmetric in the two hypotheses. 
The gain for choosing the right hypothesis is the same for both hypotheses. We shall 
let u^oo ~ 100 = Wfii and = 0 = The choice of 100 is in the middle of 
the values U^QQ = 125 and = 75 considered in the last section. Hence, the two 
examples are comparable to each other, in ways that we shall see. 
Figure 2.10 shows, for the TPRT, the gain function V^(pol"0 ~ 1) versus pg, 
for r < 5 and pg 6 [0, .5]. By Proposition 1.2, this V-function is symmetric about 
PQ = .5. This "left half" of the graph has all the information of the whole graph, and 
allows for more detail. Note that the expected net gain increases with the truncation 
time T. This means that if we plan a procedure with more sampling periods, then we 
can expect to gain more than from a procedure with fewer sampling periods available. 
The V-function converges for each fixed jag» T increases. This was proved by Cressie 
and Morgan (1986a). We see that in this example the convergence is slow. Values 
for this figure are given in Table 2.8. 
Figure 2.11 shows, for the VPRT, the gain function (pg) versus pg, for T <5 
and pg G [0, .5]. We note that for each fixed pg, when n-optimization is used, the 
convergence of (pg) as T increases, is more rapid than the convergence of the 
corresponding TPRT gain function. Values for this figure are given in Table 2.9. As 
we have seen in Example 1, we note that VQ(PQ) > V^(pg|ng = 1) for moderate 
values of pg. This can be seen by comparing Figures 2.10 and 2.11. This is perhaps 
better seen in Figure 2.12, a 3-dimensional graph of both Vg^(pg|ng = 1) and Vg (pg) 
versus pg versus T, for T <3 and pg G [0,1]. It shows that if we have more future 
sampling periods available to us, we can expect to gain more after the first sample 
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is taken than if we had only one sampling period. Values for this graph are given in 
Tables 2.8 and 2.9. 
Figure 2.13 is a graph of the optimal sample sizes tiq versus pg for the VPRT. The 
optimal sample size UQ generally increases to a maximum of 10, and then decreases. 
Data for this figure are presented in Table 2.10. 
In Figure 2.14 and Table 2.11 we present, for T = 1, the type-1 error versus 
PQ, for the VPRT and the TPRT. These functions have nearly the same shape as 
their counterparts seen in Example 1. A notable difference is that the type-1 error is 
slightly larger for each pQ for Example 2 than that for Example 1. The same comments 
made for Example 1, about the near-convexity of the type-1 error functions and the 
"saw-tooth" nature of the function for the VPRT, also hold for Example 2. As in 
Example 1, the type-1 error for the VPRT is substantially less than that for the 
TPRT for most of pQ G [0,1]. We see from Table 2.11 that, for the VPRT, the type-1 
error is less than .05 for pQ > .6. For the TPRT however, the type-1 error is less than 
.05 only if pg ^ .75, approximately. If one were to plan a procedure with the VPRT, 
then the type-1 error would be acceptably low for pg G [.6,1]. For the TPRT, on the 
other hand, the type-1 error would be acceptably low for pg € [.75,1]. Thus, as well 
as the advantage of maximal expected net gain, the VPRT has an extra advantage 
over the TPRT in that it yields an acceptably small type-1 error over a larger domain 
of values of pg. 
We see in Figure 2.15 and Table 2.12 a graph and values of the type-2 error 
versus pg for the TPRT and VPRT. As in Example 1, we note that the type-2 error 
for the VPRT is less than that for the TPRT over most of pg G [0,1]. Equivalently, 
the VPRT has power at least as large as that of the TPRT, for any fixed value of 
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PQ, except for a small range of small values of pg- Thus, as before, the VPRT yields 
simultaneously a maximal expected net gain, smaller type-1 error and larger power 
than does the TPRT, over most of pg G [0,1]. We also observe in Example 2, as in 
Example 1, the same saw-tooth phenomenon of the VPRT's type-2 error as a function 
of PQ. Again, in this example, it appears that, for T = 1, optimizing on sample size 
relative to one-at-a-time sampling has the advantage of yielding a procedure with 
greater power for any given type-1 error. This conclusion holds over most pg € [0,1]. 
Figure 2.16 is a graph of TT (the power) versus a (the type-1 error) for the VPRT 
and the TPRT. We see that, as for Example 1, for any value of a the power for the 
VPRT is greater than that for the TPRT. Note in particular that for a = .05 the 
power for the VPRT is about .94 but that for the TPRT is only about .28. Both 
the type-1 error and type-2 error were computed as functions of pQ, and presented in 
Tables 2.11 and 2.12, respectively. Values for this graph can be inferred from these 
two tables together, since the power is obtained from the type-2 error by subtraction 
from one. Both TT and A are parameterized by PQ. There is not much difference 
in the relationship between the power and type-1 error for the two examples. The 
symmetry (or lack thereof) of the parameters Uf^j does not affect this relationship. 
In general, all of the observations made for Example 1 are also made for Ex­
ample 2. The symmetry (or lack thereof) in the gain parameters for the two 
hypotheses has little effect on type-1 and type-2 errors. 
In comparisons of the VPRT and the TPRT, the same conclusions hold whether 
or not u^oO = "<11-
Figure 2.17 is a graph of (pol"0 ~ 1) versus M, for /uj € [.25,2] and T < 5. 
We note, as in Example 1, that the expected net gain increases with m for a fixed 
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value of pQ, and we conjecture that the functions are concave. We note as before 
that V(^(pol^O ~ 1) increases with T. Data for this figure are given in Table 2.13. 
A similar graph for the VPRT of (PQ) versus /ij, for FII E [.25,2] and T < 5, is 
presented in Figure 2.18. The functions go up more steeply and then level off more 
rapidly, as /ij increases. The V-functions increase with T, as they must. Data for 





















Figure 2.10: (pqI'^O ~ versus pQ, pQ € [0,1], T < 5; Example 2 
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Table 2.8: {pqIuq = 1) versus pQ, pQ 6 [0,1], 
T <5; Example 2 
PO 0.00 0.05 0.10 0.15 0.20 0.25 
1 99.000 94.009 89.134 84.537 80.392 76.752 
2 99.000 94.095 89.671 85.858 82.629 79.959 
3 99.000 94.243 90.304 87.112 84.514 82.437 
4 99.000 94.413 90.897 88.175 86.022 84.324 
5 99.000 94.576 91.416 89.048 87.212 85.778 
PO 0.30 0.35 0.40 0.45 0.50 
1 73.716 71.297 69.518 68.498 68.159 
2 77.824 76.202 75.055 74.364 74.138 
3 80.796 79.559 78.701 78.174 78.018 
4 83.000 82.001 81.3i7 80.909 80.774 



















Figure 2.11: (PQ) versus PQ, PQ 6 [0,1], T < 5; Example 2 
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Table 2.9: (pg) versus PQ, PQ G [0,1], T < 5; Example 2 
PO 0.00 0.05 0.10 0.15 0.20 0.25 
1 99.000 94.010 89.134 87.190 86.185 85.478 
2 99.000 94.485 91.647 90.129 89.158 88.499 
3 99.000 94.882 92.546 91.189 90.294 89.660 
4 99.000 95.112 92.969 91.740 90.865 90.250 
5 99.000 95.248 93.256 92.048 91.208 90.596 
PO 0.30 0.35 0.40 0.45 0.50 
1 85.004 84.754 84.525 84.391 84.318 
2 88.022 87.715 87.514 87.374 87.334 
3 89.193 88.864 88.657 88.543 88.500 
4 89.789 89.474 89.269 89.146 89.100 
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Figure 2.13: Optimal sample sizes TIQ and associated continue-sampling intervals 
[PO,i'PO,z+l) for T = 1, Example 2 
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Table 2.10: Optimal, sample sizes HQ and associated continue-sampling intervals 
[P0,z'P0,2-M) for r = 1, Example 2 
_ _ _ _ _ _ 
PQ [.000,.118) [.118,.128) [.128, .152) [.152,.199) [.199, .298) [.298, .455) 
nj 10 9 8 7 6 5 
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Figure 2.14: Type-1 error versus pQ, TPRT and VPRT; Example 2 
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Table 2.11: Type-1 error versus pg, TPRT and VPRT; Example 2 
ÔIÔE ôlô ÔTÎ5 025 Oô or 
VPRT 1.000 1.000 1.000 0.303 0.178 0.152 0.112 0.098 
TPRT 1.000 1.000 1.000 1.000 0.812 0.725 0.636 0.547 
PQ 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 
VPRT 0.086 0.076 0.067 0.059 0.051 0.044 0.037 0.036 
TPRT 0.462 0.382 0.308 0.242 0.183 0.132 0.089 0.055 
PO 0.80 0.85 0.90 0.95 1.00 
VPRT 0.028 0.027 0.000 0.000 0.000 
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Figure 2.15; Type-2 error versus pg, TPRT and VPRT; Example 2 
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Table 2.12: Type-2 error versus pg, TPRT and VPRT; Example 2 
PO 0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 
VPRT 0.000 0.000 0.000 0.027 0.028 0.036 0.037 0.044 
TPRT 0.000 0.000 0.000 0.000 0.030 0.055 0.089 0.132 
PO 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 
VPRT 0.051 0.059 0.067 0.076 0.086 0.098 0.112 0.152 
TPRT 0.183 0.242 0.308 0.382 0.462 0.547 0.636 0.725 
PO 0.80 0.85 0.90 0.95 1.00 
VPRT 0.178 0.303 1.000 1.000 1.000 
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Figure 2.17: V^(pQ|nQ = 1) versus /zj, 6 [.25,2], T <5 (Function coincides 
with the x-axis for T = 0); Example 2 
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Table 2.13: (pQ\nQ = 1) versus 
/ i i e [ . 2 5 , 2 ] , r < 5 ;  
Example 2  
n 0.250 0.500 0.750 1.000 
1 53.974 58.884 63.604 68.159 
2 55.191 61.933 68.313 74.138 
3 55.978 64.048 71.502 78.018 
4 56.552 65.674 73.883 80.774 
5 56.990 66.981 75.756 82.819 
n 1.250 1.500 1.750 2.000 
1 72.368 76.363 79.856 83.134 
2 79.289 83.707 87.383 90.350 
3 83.457 87.796 91.110 93.549 
4 86.211 90.264 93.129 95.068 
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Figure 2.18: V^{PQ ) versus M, M £ [.25,2], T <5 (Function coincides with the 
x-axis for T* = 0); Example 2 
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Table 2.14: (PQ)  versus /ij, /zj £ [.25,2], 
T < 5; Example 2 
n 0.250 0.500 0.750 1.000 
1 56.044 68.692 78.336 84.318 
2 57.131 71.542 81.577 87.334 
3 57.695 72.817 82.917 88.500 
4 58.028 73.588 83.656 89.100 
5 58.268 74.085 84.121 89.456 
n 1.250 1.500 1.750 2.000 
1 88.155 90.692 92.496 93.732 
2 90.793 92.995 94.471 95.502 
3 91.744 93.782 95.098 96.078 
4 92.223 94.133 95.440 96.305 
5 92.497 94.366 95.595 96.408 
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2.5 Conclusions and Future Research 
We need to study the effects, on expected net gain and power, of the discount 
factor T, and the variance cr^ of the Gaussian distribution. Also, we could explore 
the effect of different cost functions, especially the effect of a start-up cost CQ. We 
could also vary the gain parameters u^j as a function of time, and examine values 
of the discount r, which could change over time. Alternatively, we could fix the 
rate of «-spending, as described in Section 1.2. Ideally, we could change the VPRT 
parameters so as to satisfy this given set of sequential tail probabiUty requirements. 
An exhaustive study of the effects of the interactions of these parameters would be 
tedious, but perhaps it could lead to new conjectures and results. 
The most interesting observation is that power generally increases by optimizing 
on sample size, at least for the case of T = 1. Theoretical results on this would 
be desirable, as well as generahzations for T" > 1. Most clinical trials presented in 
the literature are based on a fixed overall a-level; other design criteria include fixed 
overall power, maximal sample size, and minimal expected sample size. Sequential 
tail probabilities are the joint probabilities of arriving at a certain stage t, and re­
jecting HQ at that stage. To see if Bayesian sequential procedures also come close 
to satisfying the needs of traditional planners of procedures, an exhaustive study of 
these tail probabilities, as a function of the VPRT parameters, would be an important 
consideration. 
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3. A BAYES PROCEDURE FOR PHARMACEUTICAL TRIALS 
3.1 Introduction 
In a recent paper, Berry and Ho (1988) presented a Hayes sequential procedure 
for the testing of (composite) hypotheses in a pharmaceutical-trials setting, where 
sample size was assumed given. However, by also optimizing over sample size, a 
VPRT-like procedure will have Bayes risk smaller than that of the Berry-Ho proce­
dure. 
Consider a two-arm clinical trial with treatment and control groups; the purpose 
is to test an experimental treatment compared to a control using the criterion of 
expected gain net of costs (expected net gain). Further suppose there is a prespecified 
maximal number T of time periods before the trial is completed. Berry and Ho assume 
that at any time point t where sampling is to continue, the same prespecified number 
of samples n is collected in each group. With two groups, this means the number of 
samples collected at each time is a constant 2 n. 
The response variable for each group is assumed to be Gaussian with unknown 
mean and common known variance. Let and be the means for the control 
and treatment groups respectively. Let 
<5 = f^ trt - fJ-ctl 
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be the parameter of interest, called the 'efficacy' of the new treatment vis à vis the 
control; a positive value of S corresponds to preference for the new treatment. Assume 
that the prior of 6 is Gau{uQ,TQ), where Gau{i>Q,T^) is notation for a Gaussian 
distribution with mean I/Q and variance TQ. 
The loss function considered by Berry and Ho is as follows: the loss is zero for 
rejecting the new treatment at any time period in the trial, whether 5 > 0 or not. 
The loss for accepting the new treatment is equal to a positive constant L if 6 < 0, 
and is equal to —KS if 6 > 0, where K is also a positive constant. So, the more 
efficacious the new treatment, the more profitable it is. 
Berry and Ho consider net loss by including as part of the loss the cost of 
sampling. We consider equivalently the negative of their loss and net loss, which we 
call the gain and the net gain, respectively. Our goal is to maximize the expected net 
gain; a procedure that achieves this is obviously a Bayes procedure that equivalently 
minimizes the Bayes risk. 
Berry and Ho specify that acceptance of the new treatment can occur only at the 
end of the trial; the trial continues to the planned endpoint T if the treatment appears 
to be efficacious, stopping early only if it does not appear to be efficacious. The idea 
is to stop investigating an ineffective treatment, but to obtain as much information 
as possible on a good one. A discussion of the merits of Bayes methods in medical 
research, and in particular the Berry-Ho procedure, is found in Berry (1987). 
The new contribution made in this chapter is to maximize the expected net gain 
over a procedure that also has sample size as a choice at each stage. For = n, 
given. Berry and Ho obtain a Bayes procedure with expected net gain that can be 
compared to that of our optimal variable-sample-size procedure. Depending on the 
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values of K and L the extra n-optimization can yield substantial improvements in 
expected net gain. 
Berry and Ho test the hypotheses 
HQ : S < 0 versus Hj^  : 6 > 0. (3.1) 
The prior probability that f < 0 is Po(^O'^o) = < 0|yQ, rg). The Gaussian 
prior on 6 is converted into a two-point prior for the purposes of hypothesis testing; 
the probabihty that HQ is true is Po(fQ,TQ), and the probability that is true is 
1 -POW'TO)-
In what is to follow, we shall examine two separate procedures. One is the proce­
dure considered by Berry and Ho, namely one-sided stopping due only to inefficacy of 
the new treatment relative to the control. That is, at each stage before the last, there 
are two possible decisions to be made, namely reject the new treatment or continue 
sampling. If the last stage T is reached, then the two possible decisions are to accept 
or to reject the new treatment. We shall call this the Bi procedure. 
The other procedure, not considered by Berry and Ho, is to permit early stopping 
due to efficacy of the new treatment, as well as inefficacy. That is, at each stage before 
the last, there are three possible decisions to be made: accept the new treatment as 
efficacious, reject it, or continue sampling. If the last stage T is reached, then the two 
decisions are to accept or to reject the new treatment. We call this the B2 procedure. 
For the and B2 procedures, theoretical results are developed for T=l, and 
numerical results are presented for larger T. We also consider the corresponding 
procedures with Bayes-optimal sampling (i.e., n-optimization) at each stage. We call 
these the B* and B^ procedures, respectively. 
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3.2 The Bi (Berry-Ho) and Bg Procedures 
The Bi procedure is a sequential decision-theoretic sampling plan to assess the 
profitability, or lack thereof, of an experimental treatment relative to a control. The 
decision to continue sampling, or to stop and accept or reject a new treatment is 
made so that the benefit relative to the cost is maximized. For example, a pharma­
ceutical company tries to maximize its expected profits. If the trial involves human 
subjects, ethical concerns about the subjects are of major importance. Quantifying 
such considerations into a loss-cost structure is not something that this society has 
so far felt comfortable doing. 
Berry and Ho consider stopping the trial early if the treatment is expected to 
be unprofitable, but continue to the predetermined stopping time T if it is expected 
to be profitable, with a critical region of posterior mean and variance (at each time 
period) at which the profitability of continuing is equal to that of stopping. The 
idea is to gain more information on a profitable treatment no matter how profitable 
it is expected to be, since this information on the treatment's performance may be 
very important for future testing (dosage levels, contraindications, etc.). The cost 
to the drug company is the cost of extra sampling. Modifying the stopping rule to 
allow for early stopping of a profitable treatment (this occurs when the present gain 
of stopping and accepting the treatment exceeds the expected gain net of costs of 
continuing sampling) yields the B2 procedure. 
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3.2.1 Notation 
Let the subscripts 'ctl' denote 'control' and 'trt' denote 'treatment'. Let the 
response variables be 
c^tl ~ <7^/2), and X^ rt ~ Gau{fitj.t, f^/2). (3.2) 
At time t, let subjects be randomized to the treatment arm and to the control 
arm of the trial. Let 
 ^= f^ trt -
Let be the break-even value of 6, such that the treatment's long-run profits for 
the company will be positive for S > 6* and negative for 6 < 6*. We can take 5* = 0 
without loss of generahty, yielding the loss structure described below. Hence, the 
hypotheses in (3.1) are appropriate. Assume that the prior efficacy is Gaussian, i.e., 
6 ^  Gau{i/Q,TQ). (3.3) 
The treatment is hot profitable relative to the control if f < 0, and the prior proba-
biUty of this is 
P0(''0''^0) = < Oko'^o) = *(-'^o/^o)' (3-4) 
where $(a;) = / ^77776""® ^^ ds. If the treatment is thought a priori to be 
J—00 
effective relative to the control then I /Q will be chosen to be large. Let 
and Xçf-i be the sample means requested at time t-1 and obtained at time t; 
i = 1, • • •, r. Let 
^0 = ^0i (3-5) 
^ t = ^ t r t , t - \ - G a u { 8 , a ^ l n i _ i ) \  t  =  ( 3 . 6 )  
I l l  
with realizations : ( = 1, " , T}, and 
E ni-iWi 




Let function of wi, - -, w^, ng, - -, i) and r^(a function of ^ "i—l) be the 
2=1 
posterior mean and variance respectively of 6 at time t; f = 1, - " , T. Expressions for 
Uf and will be given in Section 3.3.1. Let 
< = 0," ,r. (3.8) 
t 
Notice that this is a function of and ^ "f—1) but when convenient that functional 
i=l 
dependence will be dropped. It will be shown below that for the hypotheses HQ : S < 
0 versus : S > 0, the posterior probability that HQ is true satisfies PF = $(a(), 
where Sf = —i = 1, • • •, T. 
3.2.2 Gain structure 
Let the symbol denote the space of possible outcomes associated with the 
random variable defined in (3.7). Let where Af : —* {0,1}, 
be a terminal decision rule as described in Section 1.3. Let the decisions 0 and 1 
correspond to choosing, respectively, the composite null and alternative hypotheses 
in (3.1). That is, we choose HQ if A((') = 0, and HJ^ if Af(*) = 1. Let K and L 
be positive constants, and let 3? be the space of real numbers. At all / = 0, • • •, T, 
consider the gain function of the true value of the parameter and of the decision. 
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Thus, Gam:3î x {0,1} —» %, which we define as follows: 
0 , if Atiwt) = 0, V6 E % 
Gain{S, = - -L , if A^ (û;^ ) = 1, and S <0 
K8 , if A^(û)f) = 1, and 6 > 0. 
(3.9) 
Rather than formulating the problem in terms of losses, as did Berry and Ho (1988), 
we can equivalently consider Gain, which can be thought of as the negative of a 
loss function. Hence, instead of minimizing risk net of costs, we look to maximize 
expected gain net of costs, or expected net gain(ENG). Berry and Ho consider unit 
cost per observation in each arm; so c(n) = 2n, where c(-) is the cost function. The 
quantities KS and L are in units of the cost. 
3.3.1 The posterior parameters of the distribution of the efficacy 6 
We shall need the following well-known proposition which can be found for ex­
ample, in DeGroot (1970, p. 167). 
Proposition 3.1 Let Xi,' •• ,Xn be independent and identically distributed (iid) as 
3.3 Some Technical Results 
Gau{S, CT^ ), with observed sample mean x. Let 6 have a prior density Gau[u, r^ ) with 
density function 7r(-). Then, the posterior density, 
density. O 
We see from this that for ui and as defined in Section 3.2.1," 




These can be expressed in terms of I/Q, TQ, ^ and ^ n^, as follows. 
i=l 2=0 
Proposition 3.2 For t = !,• • • ,T, the posterior distribution of S at time t is Gaus­
sian with mean and variance where 
t 
+ ^0 Z ^ i-m 
vt = ' (3.12) 
z=l 
and 
T? = • (3.13) 
^0 è "t-1+ 
2=1 
Proof: We proceed by induction on t. For t=l, 
(t^o/Tn) + (nowi/o-^) 
^ (I/tq ) + ("o/o^) 
+ ^"0 VI 
r^no + 0-2 
and 
r^no + 
Assume that the result is true for t; prove it true for t+1: 




/ 2 2^ 
i=l 
^0 E "i-l + 
. i=l 
^0 È "i-l + 
\ Z=1 
n{ + 0-2 
2 2^^ i/Q'^ +T0 L "i-iw'i 
e=l 
gW 2 
^0 É "z-l+^ 
i=l 
TlfT^  + 
^0 E "i-i + «^ 
if 2: "i-i Kf' 
\  1=1 
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3.3.2 The predictive distribution of the sample mean difference 
seen at time t+1 
Recalling (3.6), is the sample mean of the treatment group data minus 
the sample mean of the control group data requested at time t and obtained at time 
t+1. It is distributed as Gau{S,cr^/nt). Integrating out 5, we obtain its predictive 
distribution. This is needed for computing the expected gain from sampling and 
continuing to the next time period. For i = 0, • • •, T—1, at time t+1 let [j/^, r^) 




1 d6 ' 
\ f/n; 
(3.14) 
where = (2%-) (•)^/2|, the standard Gaussian density function. 




n± too 1 
— —^—- / —exp 
ari -oo 27r 
1 
.-21 .2 d8 
M+1 -
(a/nJ/^)ri(27r)l/2^''^ 2(r2 + («r^/n^)) 
/: •oo CO 1 (27r)l/2 
1 
exp 
(27r)V2(cr/7zJ/^)r^ [T}  + ((r^/n^)}^/^ 
ijt + L _ T'f^f+l + 
2T^(f2/mf) \ + (f2/n;) , 
(u;^+l - ut)^  






Wj+l - n 
• 
{T^2^.(^2/„^)}1/2^ 
3.3.3 The gain functions for the hypotheses HQ and 
We now present the Berry-Ho procedure using terminology similaf to that used 
for the VPRT (Cressie and Morgan, 1986b), and set out in Section 1.3. Let U>Q and 
wj represent the values of w under the hypotheses HQ, and HI, respectively. We see 
that (3.1) and (3.9) imply that 
^too = o = "^oi; < = 0,---,T, 
and that 
"UO = 
by (1.3). Define for any t Ç {0, • • •, T}, 
"m(Pt^ N) = E {KS\6 > 0, UT,TT) . 
Proposition 3.4 Let Ufii{pf,Ti) = E {K6\6 > 0,i>f,T^ ). For t — 0,-• - ,T, 
where ((){•) and $( ) are the density and cumulative distribution function respectively 
of a standard Gaussian random variable, Sf is given by (3.8), and = 0(5^ ). 
Proof: We have shown by induction in Proposition 3.2 that the posterior distribution 








The second equality follows from (3.9). The third follows using the transformation 
z = {^ -H)ht- ^ 
3.3.4 The expected gain function of stopping at time t, conditional on pf 
and Tf; 
Analogous to the gain function (1.3) for the VPRT, we have a gain function for 
the B-procedures. We have the following definition. 
Definition 3.1 A gain function for testing HQ versus at time t, is a mapping 
UF : Q, X {0,1} —» where fi = {WQJWJ} and 
0 ,ifAt{wt) = 0 
—L , if Af{ûn) — 1 and w = wg 
Euji[KS\{pt,Tt)] , if Ai{ivi) = I and u) = uy, t = 0,--',T. 
As we have seen for the VPRT in (1.8), the maximal expected gain function of 
stopping at time t, conditional on the data and prior, is 
Euj At(wt))\pt, Tt] = max{uiQQPt + utQi(1 -pt), HiQPt + umipt, r^)(l-Pt)], 
(3.15) 
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where A^(*) is a terminal decision that will be formally defined in Section 3.5, 
are the gains at time t for choosing state i when state j is true, as defined in (1.3), 
and w = are the states of nature corresponding to the hypotheses HQ and 
respectively. For constant values (i.e., not depending on the posterior 
parameters), as is the case for the VPRT, we have seen (in Chapter 1) that the 
maximal expected gain function of stopping has a simple functional form; it is the 
maximum of two intersecting straight hnes, as a function of pf. For the Berry-Ho gain 
structure (3.9), (3.15) (as a function of p^) it is the maximum of a straight line and 
a curved line; we shall now demonstrate that these two lines intersect at exactly one 
point. To do this we must examine the properties of the function (3.15). A building 
block of this function is the posterior probability pi that is true. 
Proposition 3.5 For the hypotheses HQ : 6 < 0 versus HJ^ ; <5 > 0 the posterior 
probability that HQ is true satisfies pi = {^S^ ), where SF = —is given by 
Proposition 3.2; < = 0,1, • • •, T. 
Proof: The proof is based on the property that the posterior distribution of 8  is 
distributed as a Gau{vi,T^) random variable; see Proposition 3.2. Then, 
after transforming with z = (6 — VQ)ITQ.  Similarly, 
Pt = = ^{H) ; ( = 1, ",2'. O 
Since = 0 = "fOl> f = 0,'"(3.15) can be expressed as 
Ew\Ut{oJ,ù.t{wt))\pt,Tt] = max{Q,utiQPt + uiii{pt,Tt){\ - Pt)}. (3.16) 
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To study the properties of this function, let us define, for < = 0, • • •, T, 
hipun) = moPt + HniPhn)i'^-Pt)i o<pt<i, >o, ( 3 .17) 
which is the expected gain for stopping and choosing when the posterior distri­
bution parameters are p^, Tf, at time t. It is also a function of K and L. Furthermore, 
hipt^ n) = mm + H\\{Phn)i\-Pt) 
= (-i)M+(1 -
= -Lpt + Kti - 3t{l - $(s<))] 
= -Lpt + Krt - ^~^ {pt){l -Pt)] , (3.18) 
for Pt € (0,1) and > 0. The second and third equaUties follow from Propositions 
3.4 and 3.5, respectively. The last equality follows since sf = #~^(p^). 
The function ht{pi,Tf) has the following stationarity property: 
hiPh n) = /(0(P0, tq) if PO = Pt AND TQ = R^. (3.19) 
We see from (3.18) that if the constants K and L are the same at all stages, as they 
are in this presentation, then the h-function is not a function of the stage, but only 
of {p,t). Hence its subscript t could be discarded. If the constants K and L were 
dynamic, that is, stage-dependent functions of t, then the subscript t is essential. We 
shall retain it to allow the possibility of a future generalization of our study. 
We can also express A((p(,T() as a function of r^: 
n) = [^ (^ <) - •s<(i - HH))] • (3-20) 
It follows that 
Ai(wt))\pi, Ti] = maa:{0, A^(p^, r^)}, (3.21) 
by (3.16) and (3.20). 
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3.3.5 Properties of h^{pt,Tt)i the gain function for choosing at time t 
We see from (3.16) that for fixed > 0, the root(s) of the function 
are breaJc-even point(s), for stopping and accepting either of the two hypotheses 
versus continuing. Hence, we are interested in establishing the existence and unique­
ness of such a point. We make the following formal definition. 
Definition 3.2 For a fixed value > 0 let be the root of the function hf{pf,Tf) 
for that particular value of Tf. 
This will be the case if Tf) can be shown to be decreasing in pt on (0,1), positive 
for Pi near 0, and negative for pi near 1. 
We now present some results that are needed later. For any continuous differen-




<^^ (x) = —x<j){x),\/x G %. 
1 — $(x) < ^(a:)^,Vx 6 %. 
^<^($-i(p)) = -$-i(p),Vpe(o,i). (3.25) 
(3.24) 
(3.23) 
The last result follows by (3.21) and (3.23). 
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Theorem 3.1 For any fixed > 0, hf{pf,Tf) is continuous, convex, and decreasing 
in pt; For any fixed Tf > 0, A((0,T^ ) = oo and A((1,T() = —L. Hence for any fixed 
Tf > 0, A((-, Tf) has a unique root ^  6 (0,1). 
The root ^ does depend on t, or equivalently, on r^, even though does not. 
Proof: 
hiPt^ n) = -Lpt + - $~^(pf)(i - p<)], 
which is a continuous function of pf. 
= -£+/fr, [-$-!(«)-|«-1(P,)(-1) + (1-K)^^54^} 
< 0,Vpf 6(0,1). 
The first equality follows by (3.22) and (3.25). Furthermore, 
^ [^(^~^(P<))(-1) - (1-Pf)(-^~^(Pf))] 
= ,4 k*'Vw))-(l-w)*"^(w)]- (3.27) 
The first equality follows by (3.25). 
To show convexity, it will suffice to show that Vpf E (0,1), 
since its coefficient in (3.27) is positive. It is more convenient here to work on the 
sf-scale; recall = $~^(pf), a monotonie increasing function of pf. Now, 
«>(«"'(?()) - (1 -w)*"'(P() = *(4) - (1 - (3-28) 
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If Si < 0, then 
- (1 - ^ h))H > = 0. 
52 
(3.29) 
This inequaUty also holds for > 0 by (3.23). Hence —ô^t{pti h) > 0 i^Pt ^ (0,1), 
dpi 
by (3.27) and (3.28). Therefore, hi{pi,Tf) is convex in pt on (0,1). 
Since Pi = ^{st), 
ht{0,Ti) = Krtl lim <f>{^  {^Pt))- Um $ (^Pf)(l-P<) 
LPf -»• 0 -» 0 
= 00. 
This last equality comes from the following well-known fact: For any random variable 
X with distribution function F{-), if E\X\^ < 00, then 
lim x^(l — F(a;)) = 0, Vg > 0. 
X  — 0 0  
(3.30) 
Therefore, 
lim u(l — $(w)) = 0, 
u 00 
and for p tending, to 0 from above. 
lim $ ^{p)p — lim u$(u) 
p —> 0 u —00 
= — hm u(l — 0(u)) = 0. 
u —y 00 
Also, for p tending to 1 from below. 
(3.31) 
lim $ \p)(l — p) = lim u(l — $(u)) = 0. 
p —» 1 u —» 00 
Therefore, 




lim ^ H^-hpt)) - lim ^ $-l(p()(l-p()) 
-> 1 pf 1 
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From the continuity and convexity of hf(pf,Tf) in and the limits as > 0 and 
Pf —*• 1, there exists a unique pt such that ht{^, r^) = 0, for each fixed > 0. O 
The root pf will of course depend on the posterior variance; when convenient it 
is written as ^(r^). To find pi in practice, we can use a first-order Newton-Raphson 
expansion (e.g., Buck,1978,p.523). Let p^ be an initial guess. 
_ -L^  + Krt L ($-1(P?)) - (P?)(l - P?)] 
— Pt r —Tt • (3.33) 
L + 
This follows by (3.18) and (3.26). We proceed by replacing p^ with in (3.33) and 
iterating until a convergence criterion ~P\\ < ^ is met. The function A/ of pi 
is shown in Figure 3.18, for the case K = 5000, X = 2000, = 1, and «Q = 0,1,30, 
and 100. 
3.3.6 Ep^  [^/(Pb7"l)b0'^0'"o]' the expected gain from sampling; T = 1 
We define ^^(piiT^) = max {0, ^ ^(p]^, r^)}, the expected gain seen at f = 1 
when r = 1. Then, 
M(Pl'n)l(P0''^0)'"0] 
is the expected gain seen at < = 1, conditional on the prior (po,TQ) and the sample 
size ng. 
The previous section has established that the function A^(p(,T^) has a unique 
root in its first argument for fixed r/, which we have called p^. Since ^~^(pf) is a 
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strictly increasing function then has a unique root 
= $-!(%). (3.34) 
We also know that is decreasing in 5^, and it is positive if and only if 
< % (3.35) 
by Theorem 3.1. 
We have seen in (3.15) the expression for the maximal expected gain at time t, 
conditional on PtiH' Taking the expected value of this expression and conditioning 
on sample size, we obtain the expected gain at the next time period t+1. This 
corresponds to Ep^ (1 10) for the VPRT. 
Now consider the truncation time to be T =1; looking ahead from the planning 
stage ( = 0, to < = T = 1, we obtain: 
Proposition 3.6 
W(pi'n)bo''ro'"o] ^  —^^^/(i(^(«),nX^, 
where s^ , b, and a(po) defined in (3.34),(3.39), and (3.40), respectively. 
Proof: 
[ViiPhTi)\P0^ '^ 0'M =/^9("'i:''0''^0)"^o®{0'^l(^(n)'n))<^^b(3-36) 
by (3.21), and noting that 5^ is a function of ujj. Indeed, for any t, from (3.8), 
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in-ilj-i) + ) 
'_iv I 
1/2 
3f-l((r^/nf- l)-Tf_iu;f  
W«Kl) W-1 + (<^^/"<-l)}^ '^^ 
$"^(pf_l)((z^/nf_l)  -  Ti_iwt (3.37) 
The second equality follows from (3.10) and (3.11). Taking t=l and solving (3.37) 
for loj we have 
""1 = 172 
"0 7-0 
(3.38) 
Then, from (3.38), Ep^ [l^(M''^l)IP0''''0'"0] equal to 
/°° q{wi ; f/Q, TQ)max {0, hi (0(51), rj )} dwi 
J—00 







$ ^(po)-^ - W + 
nJ 
max {0, hi (0(w), rj)} du. 




where the arguments Tf,ni,a are omitted for convenience. 
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by Proposition (3.3), and (3.34),(3.35), and (3.39). Therefore, 
EFQ [i'i'(pi.n)lpo.''o."ol 
=  i r  *  0 J—oo 
(l 
b $ ^(po) 1/2 W + («^^/"o)} ^ " 
"0 




Again, for any t, let a(pf;r^,n^,o") be defined as 
1/2 
a{Pt) = {rf + (o'^M)} $ ^(Pf), 
where the arguments r^,n^,(T are omitted for convenience. 





Ai($(u),Ti)(fu.  (3.41) 
• 
Notice that, as a function ofpQ,TQ,nQ, Ep^ (Pl, ^ '1 )IPQ, D, ^ o] identical to 
^Frp_i l^f T)!Pr-l. tT-1 ' "r-ll > ^ fonction of pj'_i, Ty_i, ny_i• This 
is the stationarity property referred to in (3.19). 
For any continuous difFerentiable functions /(•,•) and g{-) we have 
^ ^ f { x , 9 { y ) ) d x - 9 ' { y )  +  f { y ^ 9 { y ) ) -  ( 3 - 4 2 )  
This is known as Leibnitz's Rule (see e.g.,Hildebrand,1976,p.365), and is used to 
prove the following theorem. 
Theorem 3.2 The function Ep^ (Pl i ^1 )IPO;  ^ 0» "o] " continuous and strictly 
decreasing in /JQ . 
Proof: Let 
K m )  =  ^ 1 — ( 3 . 4 3 )  
a function of tqjUq, and a as well as of pg- Let 
z = (3.44) 
Then, 
w = 6z 4- o(po) = 6(z - y(po)) + (3.45) 
Therefore, 
[^^(Pl,n)IP0i'^0,^0] = /ii($(u),ri)(fu 
= <^(z) - (0(6(z -  y(po)) + 61 ), Ti) dz. 
J — oo 
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By (3.40) we have 
[W(pi.n)lPo.'-o."ol = M(n,n)lpo,''o.''oi • % • 
which is equal to 
lit"' (*(»(' - "(î'o)) + Sïï.n)"'-1 • ^ 
= {y^oo - y) + ^ ), n) (fz + Ti) j • 
1/2 
= - ^ V (^t-i"°o)) /-°° 
The first equahty is Leibnitz's rule and the second equality follows from 
/il($(Sj),Ti) = 0, by (3.34). Furthermore, 
= Tp^hlp-n)) • ^ ^ 
= nl^'^'^[L<f>{u) + KTi{l-^u))]. 
Then, 
[''/(pi.n)lpo.''o.»oJ 
F (P{Phi (PQ)) J—OO 
< 0. 
129 
The last inequality follows since the constant is positive, as is each summand of the 




l im ^[ l^i^(Pl ,n)b0' '^0 '"0]  = oo-
= -4 rL { i m  
n J l .  ( 3 . 4 6 )  
by Proposition 3.6 and (3.20). Let e > 0. By (3.31) there exists a constant ^4 < 0 
such that if ti < A then 
— e < u$(u) < 0. (3.47) 
Now, lim EjTi M(Pl,n)IP0'^0'"0l equal to 
PQ —+ 0 «J 
-L lim Y H-— ( T  ^  (j){-—^^)(j){u)du 
PQ—^ObJ—oo 0 0 PQ —+ 0  oo 0 
- ]im <f>{z){bz + a(pQ))dz + ^ lim f ^ <^{-—r^^)$(u)uc?«| 
PO PO ^ J 
(3.48) 
= -L lim (f>{z)^{bz + a{pQ))dz 
PQ —> 0 •'—oo 
+ Kti lim (f>{-—^^^)(f>{u)du - lim 6 (f>{z)zdz 
I 0 J—oo PQ —• 0 0 PO ^ ^—oo 
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- lim a(po)^(y(Po))+ À 
PQ —> 0 /JQ 0 ° J—OO 0 
+ Urn i ^(lz.^)$(„)„du|. (3.49) 
Pq —• 0 à JA 0 J 
We obtain (3.48) from (3.46) since 
1 ^ ~ udu = + a(po))<!z, 
transforming with (3.43) and (3.44). We obtain (3.49) from (3.48) by transforming 
with (3.44) in the first summand, and by the Lebesgue Dominated Convergence 
Theorem (LDCT) (e.g., Royden, 1971, p. 88) in the second summand. the By (3.47) 
and by the LDCT, the right-hand side of (3.49) is greater than or equal to 
-£ Urn ^{z)dz + KTI I -  hm o(po)0(2/(po)) 
PQ -+ 0 J—OO PQ -» 0 
+po"" 01 /I 
> — L lim $ 
PO -+ 0 
= oo. 
• 
Proposition 3.8 lim Ep fv/(pi,ri)|po,ro,nol = 0-
pn —^ 1 ^ PO 
Proof: 
lim [tY(Pl,Ti)|P0,T(|,n|)j 
= -i Um i n 4^ ^ :^Z )^^ u)du 
Pq —» 1 0 J—oo 0 
+/Cti lim / ^ (f){-—^^^) • [(f){u) -  u(l - 0(u))] du 
I 0 PO —1 J—OO 0 
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The first integral is 0 by the LDCT, since $(w) G 2/^(—oo, aj), the set of Z.^-integrable 
functions on (—00,51). The second integral on the right-hand side is 
«•r i l  Urn i /"  
IPO ° J—00 0 
+ lim i /•"' - u(I - «(u))rfu| i SÎ > 0, 
PQ —1 0  ^ 0 0 J  
or IS 
JfTil  l im 1 /"  IpQ —> 1  0  ^ —00 0 
- Urn i ^("-°(''0))(^(„) _ „(1 _ 4(„))<i„ 1 ;5J < 0. 
PO 1 6 V51 0 J 
In either case, the second integral in both of these expressions is 0 by the Bounded 
Convergence Theorem. 
Furthermore, 
(!>{-—~^) < for PO > 5 anj  V« < 0,  
which implies that 
W")-41-$M) < + I«I(1 - *("))) € i'(-c»,0). 
Therefore, 
lim , Ep M(pi,TI)|PO,TO,"O] 
n —>• 1 u PO 
= KT] lim f < ^ ( - — —  " ( 1  —  ^ {u))du 
PQ —1 J—00 0 
= 0, 
by the LDCT. • 
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Corollary 3.1 EP^ - c("o) , a function ofpQ (TQ and UQ 
are fixed), has a unique root in the unit interval (0,1). 
Proof: This function of pQ is oo at pQ = 0 by Proposition 3.7. It is continuous and 
strictly decreasing by Theorem 3.2. It is —c(no) at pg = 1 by Proposition 3.8. Hence 
a unique root exists. 
We make the following formal definition. 
Definition 3.3 For any fixed constant TQ > 0, let pQ jj be the unique root pQ E (0,1) 
of 
[^(Pl ,n)IP0'D,"0] -  4"o),  
the continue-sampling critical point for the B-^ and B2 procedures. 
Corollary 3.2 Let pQ, defined in Section 3.2, he the root of the function AQ(pQ, Tg) 
for a fixed value of TQ > 0. If 
^Fq - c(no) > 0 
then 
^FQ [^/(Pl.n)b0''^0'"0] -C("O)' 
as a function of pQ, has a unique root pg (y E (pQ, 1). 
Proof: The existence and uniqueness of the critical point was established in Corollary 
3.8.1. It is necessarily between the root of ftgC") ') ^.nd 1, since 
Ejp^ (f'l ' n)IPO' ^ 0' "0] -c(Mo) is a strictly decreasing function of pQ, by Theorem 
3.2. O 
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3.3.7 Properties of $""^(*), the inverse of the gaussian distribution func­
tion 
We have seen in (3.18) an expression for 
hivUH) - -Lpf^ Kti -P()] , 
the gain function for choosing : 6 > 0 at time t. It is a function of the posterior 
probabiUty that HQ is true, and the posterior standard deviation of 6. Since we 
are interested in the hypothesis testing problem, we examined the properties of this 
as a function of pf, for a fixed value of Tf, We see by inspection that, as pf —> 0, this 
function is essentially proportional to In order to understand the behavior 
of the gain function as —» 0 (for fixed r^) we give a more familiar expression for 
^~^ipt) in this section. Using ideas from a paper by Strecok (1968) we have the 
following result. 
Proposition 3.9 
( ) lim r79=l-
P 1 {-2log [4p(l - p)])^'^ 
( ) lim ^ TTo = 1-
p -+ 0 -{-2log [4p(l - p)]}^'^ 
Proof: Let $(a:) = p. 
lim 
p-^l {-2/o^r[4p(l -p)]}^'^ 
(a) The limit, is equal to 
lim 
s oo [4$(x)(l - $(x))]} 1/2 
= / r 1 




z —» oo 
^1/2 
40(z)(l-0W) • J 
by L'Hospital's rule (e.g., Hildebrand, 1976, p. 604). This is equal to 
/  , ,  z( l-$(T))lV2 r 0(z) 1 
|l -iPcX3 <^(z) J |x -^CX5 2$(x) - 1J 
I® oo -x(j>{x) } '  
by L'Hospital's rule and (3.23). Furthermore, this is equal to 
I X o^o x^{x) J I X -» oo çj(a:)(l -x^)) ' 
again by L'Hospital's rule. This is equal to 
| l -  lim —= 1. 
\ X CO 1 _ a;2 J 
(b) The limit, lim ^ is equal to 
P 0 -{-2log[4:p{\ -p)]} '  
lim ® 
x-*-oo _ {_2log [40(x)(l - 0(x))]}V2 
= lim 
X -> oo ^_2iog [4(1 _ $(x))$(x)]}l/2 
= 1, 
by part (a). 
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3.4 Theoretical Results 
3.4.1 9t{Pti'''t)> the gain function at time t minus the expected gain net 
of costs at time t+1 
Let 
for < = 0, • • •, r — 1. This is the gain seen at time t less the expected gain net of costs 
at time t+1. Its roots are points on the )-plane. For any t and for any fixed 
r^, the root of this function, if it exists, is denoted and is used in defining the 
B2 procedure. For any t and for any fixed T(, the root, if it exists, of 
as a function of p(, is denoted p^j, and is used in defining the B-^ and B2 procedures. 
For fixed if pl is the root of r^), and if 
then piu exists and is unique (by Corollary 3.8.2). In this section, we discuss the 
existence of the lower root pj.j^ used in the B2 procedure. 
The existence of unique roots would guarantee that the unit interval is parti­
tioned into three regions for the B2 procedure. For fixed the middle interval 
\PtLiPtu\ the continue-sampling region for p/. The intervals [0,p^^) and (p^f/, 1] 
for pf, correspond to stopping immediately and choosing the hypotheses Hand HQ 
respectively. 
We must examine the properties of the function (3.50) in order to establish the 
existence and uniqueness of the roots, and to find the asymptotic values of gtipti'^t) 
(3.51) 
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as —»• 0 and PF 1, for a fixed value of > 0. It will be shown that for T=1 
we have for any tq > 0, 3'o(0,To) = c(no) > 0 and 5^0(1, Tq) = -Z, + c(no). Thus 
provided c(NO) < L, the continuity of g{-,TQ) for any fixed TQ will guarantee at least 
one root. A sufficient condition for uniqueness would be that g\-) is monotonie 
decreasing, however it is unfortunately a complicated function of the parameters 
K, L, TQ, and cr^. The function g{-) appears to decrease steadily in many numerical 
examples considered, but it is not convex in general. These phenomena have also 
been observed for T > 1, but they are only conjectures. More research needs to be 
done on the properties of this function, although present investigations indicate that 
results will not be simple. 
Proposition 3.10 For any fixed TQ > 0, 
lim _fl'0(P0''^0) = ^("0)• 
P0 0 
Proof: For any fixed TQ > 0, 
lim _90(P0'r0) 
PO 0 
lim {-LPQ + KT Q  [ ^ ( $ ~ ^ ( P O ) )  -  - P O ) ]  
PO " 
- l l i i - m i u )  4- Kri {Hu) - «(1 - $(«))}] du 
-
= c(no) + lim KT Q  U( $ ~ ^ (po) )  +PO^ ~ ^ (po) )  
PO -> U ' 
+ lim [-/CTO$~^(PO) +  ^ <TIT J ^ 4-— 
Pq —• 0 1_ 0 —oo 0 
- lim \ -j. KTI {^(u) + u$(u)}] du. (3.52) 
PO -+ 0 0 J—cxi 0 
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The integrand in the leist integral of the expression above is 
^("-q(Po))  + KTI + «$(«)}] 
< —^ \-L^u) + Kri {^(«) + u^u)}\. (3.53) 
(27r)V^ 
We shall show that the right-hand side of this expression is integrable on (—00,3%). 
Since $(u) and <f>{u) G 00,^), it will suffice to show that u$(u) G 00,6%). 
rST rsi xi^ 
I ^{u)udu = $(u)— — I -—<f>(u)du, 
y—00 6 —00 J—00 Z 
using integration by parts. This is finite since 
lim = lim (1 — = 0, 
U _» -00 U-KX>^ ^ " 
by (3.30). Then the expression on the right-hand side of (3.53) 6 Z^(—00, sj) .  Thus 
the last integral in (3.52) is zero by the LDCT. The first limit in (3.52) is zero by 
(3.31). Then, lim ^fo(PO)^o) equal to 
PO 0 
c("o) + + n 1'''°')"'^"} 
= c("0) + ^  Hm { - tq^'HPO) 
PO ->-O 
, 2 _  
+ n 




= c{nQ)-\rK lim { -rQ$ ^(pg) 
PO 0 
-f-To$~^(po)-n —^^)udu } 
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= c(no)-/fr i  Hm L —^^)udu. 
PQ —^ 0 3 2 " ^ 
(3.54) 
It is easy to show that 
PO"2 o/sT = p/î; o/o°° 
•00 
FO "^1 //y-rv/'w -
by the Bounded Convergence Theorem. We also have that 
Li lim 
PO 0 ,rA3 udu • exp b J 
lim exp = TTô" u ^ (27r)v2 po -+ 0 
= 0. 
.1 ^ g(po)y 
The second inequality holds since a(po) < 0 for sufficiently small pQ. Then, 
Urn yr -rH 
PO — *  O J s i  0  
°° ^ °(po) )udu = 0. 
By (3.52), 
lim .gofPO'To) = c(no)' 
PO 0 
• 
Proposition 3.11 lim fl'o(PO'^o) ~ + c(no). 
PO 1 
Proof: This follows by Theorem 3.1 and Proposition 3.8. O 
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3.5 Formal Definition of the B-Procedures 
The B-procedures will now be defined. A (sequential) decision rule to choose 
between two simple hypotheses consists of a stopping rule, a sample-size rule, and 
a terminal-decision rule. We have seen definitions of these for the VPRT in Section 
1.3.1. We shall define counterparts of these for the B-procedures. Let the symbol 
denote the space of possible outcomes of the random variable Wf. 
3.5.1 The B2 and procedures 
For the procedure, we shall use the optimal sequential sampling plan of an 
optimal procedure to be defined below. Recall, from (3.18), the function hi of 
both Pi and r^: 
hiPhn) - -LPt + - Pi)] • 
This is the maximal expected gain function for choosing as a function of both 
Pi and r^. Should the procedure specify to stop at time t, the expected gain is 
maximized by choosing, analogous to Definition 1.1, a terminal decision procedure. 
(%) = 0 p,;;, 
1 \ h i p u n )  >  
We have seen in (3.16) an expression for [^[/^(w, A^(tD^))|p^, T^j, and noted that 
it is a function of both pt and r^. Should the decisionmaker sample until t = T is 
reached, then a terminal decision must be made. Thus the expected gain a.t t  = T of 
a sequential decision rule d incorporating A^(') is defined to be 
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where an expression for the right-hand side is given in (3.16). At time f = T — 1 the 
decisionmaker can either choose between WQ and wj using (3.55), and expect a gain 
of 
Eu [t^r-i('*''^r-i('^r-i))l(pr-i'^T-i)l > 
or he can collect > 0 additional observations and expect, for any sequential 
decision rule d, a net gain of 
-c{nrp_i) + , 
where Ep^ ^ denotes the expectation with respect to the unconditional cumulative 
distribution function of the 1 observations asked for at i = T — 1. 
Thus, the expected net gain of continuing to sample at ( = T — 1 is maximized 
by choosing, for a sequential decision rule d, the sample-size rule as 
^r_l(^r- l)  = '"'T-l 
e argmaxl- c{n'j^_i) 4- Ep V^{w'j^,d,{pj',Tj'))\{pj'_i,Tj'_i),nj<_i\\ .  
ny_l >0'-
Furthermore, the expected net gain at i = T — 1 is maximized by choosing, for a 
sequential decision rule d, the stopping rule 
5f_i(û)y_l)  
+ l^ T (PT' TT))l(pr-i' ^ T-i )' ^ r-1 (^r-i)| 
1; otherwise, 
and the maximal expected net gain is 
= max{Eu) [(/T-l(^)^T-l(^T-l))l(PT-l''^T-l)] ,-c(<^r-l(^T-l) 
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+ ^Fj>_i \yT (PT' ^ T))l(pr-1 ' ^ T-l)' *r-l ("T-l)) }-
Backward induction yields the following (Bayes) sequential decision rule, 
rf^ = (5*,$*,A*): 
(a) A* = {A^}^q , where 
0;  i f / i i (Pf ,Tf)  < 0 
1; if /t((p^,T() > 0. 
(b) }^o ' ^U'^t) 
e argmax\^ c(n^) + J^+l(^<+l,4, (Pf+l,))|(p<,T^),j 
;  < =  0,•  • •  , r -  1,  
and 
^y(û)j') = 0. 
Recall that Edenotes the expectation with respect to the unconditional cumulative 
distribution function of the Uf observations collected at time t, defined by (1.5). 
(c) S* = where 
0; if max[Q,hl{pt,Tt)] < -c($^(û>^)) 
+ Ep  ^ ,4 ' in+hn+i))\iPhn)^(^^)] 
; t  = 0, - • • ,T — I, 
1; otherwise, 
and 
S^{wj') = 1. 
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The sequence of maximal expected net gain functions implied by is 
= max[Eu 
and 
vf{w'jp,d2,{px,'rT)) = [Uj'{uj,Ax{w'jp))\{pj',Tj')j. (3.56) 
Call the sequential procedure the procedure. 
The B2 procedure is defined by (a) and (c) where {$*} is replaced with a 
suboptimal a priori specified sample size rule by backward induction it is 
ENG-maximizing (Bayes) for that sample-size rule. 
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3.5.2 The Bi and procedures 
In the procedure given by Berry and Ho (1988), they did not consider at any 
time period t before the last, the possibility of accepting the experimental treatment. 
That is, they did not allow acceptance of until t = T. At all time periods prior 
to the last, they considered only the gain for stopping and rejecting the experimental 
treatment, and the expected gain net of costs for continuing to sample and proceeding 
to the next time period. The gain for stopping is zero at all time periods prior to 
the last. Hence, if a terminal decision is reached at < < T, this decision can only be 
to choose HQ (corresponding to rejection of the new treatment). Thus, should the 
decisionmaker decide to stop at time t, the expected gain is maximized by choosing 
a terminal decision procedure, 
0  ]  a t < T  
A*(?D() = < 0 ; if i = T and < 0 
1 ; if < = T and h'j<{prp,Tj>) > 0. 
The expected gain at < = T of any sequential decision rule d incorporating A^(-) is 
defined to be 
V^{wT,d,{pT,TT)) = Eu [i7y(a;,Ay(tï;y))|(pj>,Tj')] . 
At time t  =  T  —  1 ,  the decisionmaker has a gain of 0 if he chooses WQ, or he 
can collect > 0 additional observations and expect, for any sequential decision 
rule d, a net gain of 
-c(nj_i)+ .  
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Thus, the expected net gain of continuing to sample at < = T — 1 is maximized by 
choosing for a sequential decision rule d, the sample-size rule as 
^r-i(^T-i) = "T-l 
G argmaxiç c{nj<_i) + {w'j',d,iPT^TT))\iPT-l^'^T-l)^^T-l]} • 
nj^_l  > 0 
Furthermore, the expected net gain at < = T — 1 is maximized by choosing, for a rule 
d, the stopping rule 
0; if 0 < 
+ l^ T (PT^ Ty)) | (pr_i ,Ty_i) ,  
1; otherwise. 
The maximal expected net gain is 
rp 
=  m a x  | 0 ,  — ( w f )  
+ [^f (PT^ r2^))|(pr_i, }• 
Backward induction yields the following (Bayes) sequential decision rule. 
(if = (5*,^*, A*): 
(a) A* = {Af}^Q, where 
= 
0; if htipt, Tf) < 0 
1 ;  h t { p t , T i ) > 0 .  
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(b) = where 
argmax^ c(n<) + ^ f^_j_2[^+l(w(+l,4, (Pf+l,T(+l))l(P(, ?'(),"<]} 
;  < =  0,"  , r  — 1,  and 
$^({02') = 0. 
Recall that Ep^ denotes the expectation with respect to the unconditional cumulative 
distribution function of the observations collected at time t, defined by (1.5). 
(c)S»={S,-}f^„, where 
S t i m )  
0; if 0 < -c(»^(w()) 
1 ; otherwise, 
and 
S^{w'j') = 1. 
The sequence of maximal expected net gain functions implied by d* is 
= max |o, —c(^|(w^)) 
+ (pt+ 
;  < =  0,--- , r-  1,  
and 
Vj{w'j<,d\,{p'j<,Tj')) = Eu [Uj'{u},A^{wj')))\{pj',Tj')j . (3.57) 
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Call the sequential procedure (i|, the procedure. By using a suboptimal a priori 
specified sample size rule }^Q, and (a) and (c), we obtain the procedure 
that is ENG-optimal (Bayes) for that sample-size rule. 
3.6 Numerical Results and Plots 
The relative merits of optimizing expected net gain over sample size, referred 
to here as n-optimization, can be presented numerically and graphically in a variety 
of informative ways. By altering the gain parameters K and L, and the variance 
parameters cr^ and TQ we can examine special cases of the B-procedures. We shall 
present first an example for which the advantage of n-optimization is large. After 
this, we shall present an example given by Berry and Ho for which the advantage (as 
measured by expected gain net of costs) is modest. The point is that n-optimization 
always yields a net gain larger than that obtained with ad hoc choices of sample size, 
but its advantage depends on the values of the parameters. 
3.6.1 Truncation time T = 1 
Define 
the posterior gain seen F^ C t  =  1  when T  =  1 .  Then, [^(Pl,7'l)|(P0)D)i"o] 
the expected gain seen at I = 1, conditional on the prior (PG, TQ) and the sample size 
rag- We shall assess the advantage of n-optimization by evaluating the expected net 
gain of continuing and collecting ng observations to be received at time T = 1; it is, 
^FQ [^ikpi>n)l(PO' '^o) '"o]  -c(no) '  
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a function of (PQ, 7'o),»0) ^ well as K, L, and cr^. For T = 1, this expression is 
common to both the B-^ and B2 procedures. Define 
Vo(P0' ' r0K) 
= ma®|maa;{0,/io(po.T'o)},-É^irQ [^I^(pi,TI)I(P0''^0)."0] " c(no)}(3-58) 
for the B2 procedure. This is the maximal expected gain net of costs for the B2 
procedure. We also define, for the B-^ procedure, 
^0^(P0'^0l"0) = M(Pl,n)l(PO'To)'^o] -c(no)}- (3-59) 
The procedure associated with Vq (P0''^0l"0) always be clearly stated. 
3.6.2 Truncation time T > 1 
We shall also examine the gain function for T > 1, to assess the 
effect of having more than one potential sampling period. 
The V-function for the Bi and 5^ procedures is different from that for the 
B2 and B2 procedures. This is due to the fact that, for the latter procedures, the 
decision to continue sampling at each time period t depends on two critical points 
and Piiji where 'L' stands for 'lower' and 'U' stands for 'upper'. However, the former 
procedures depend at each stage on a single continue-sampling critical point p^y. We 
compute the gain function (3.18) by incrementing rg over a grid, and incrementing 
PQ in small steps over the unit interval (0,1), solving for vq through the relation 
PQ = $(—shall use unit cost per observation in each arm of the trial; i.e., 
c(nQ) = 2nQ, since each arm has the same number of observations. 
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3.6.3 Example h K — 100, L = 5000, = .5, TQ = 1 
Consider first the case T = 1. Fixing TQ = 1, we can plot the optimal sample size 
ng versus pQ for the procedure with T = 1. It happens that for the parameters 
of this example, the gains change substantially for sample sizes ng < 10. As we shall 
see for the parameters of Example 2, however, there is negligible change in expected 
net gain between that attained with a sample size ng and with a sample size ng + 1. 
For Example 1 we shall consider sample sizes one unit apart in our optimization. But 
for Example 2, it is expedient to consider multiples of five as sample sizes for our 
n-optimization. We see in Figure 3.1 that Mg is 0 for pQ sufficiently close to 0 or to 
1. We call the pg-interval corresponding to ng > 0 the 'continue-sampling' interval. 
In this region the optimal sample size increases steadily, and then decreases. Note 
that one would reject the new treatment immediately if pg > .737, or accept the new 
treatment immediately (B^-procedure) if pg < .001. Numerical values for this plot 
are presented in Table 3.1. The same plot of optimal sample size ng versus pg for 
the B* procedure with T = 1 was done, and is presented in Figure 3.2 and Table 
3.2. The critical points and corresponding optimal sample sizes ng are identical for 
both procedures, as they must be, on the interval (pi£, 1.]. We see in Table 3.2 that 
ng = 1 is optimal on the interval (.0, .002] for the B^ procedure. This means that if 
one were to sample at least one unit, then a sample of size one would be optimal on 
this interval. But, if one were to consider also a sample of size zero, as does the B^ 
procedure, then it is optimal to take no samples on the interval (.0, .001]. We also 
see that for the parameters considered here, ng = 5 is the global maximum sample 
size that we need to consider. In order to know this, however, we had to compute 
the expected net gains using values of ng much larger than five. 
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To demonstrate the effect of sample size on expected gain net of costs when 
r = 1 we can plot Ep^ (Pbn)KPO>'^o)'"o] ~ c("o) versus pg, for various ng. 
Figure 3.3 is a contour plot of the surface (Pl, H)l(PO) D)» "o] ~ c(nQ) for 
• 1 < PO — and ng from 1 to 21 in steps of 2. This shows the joint effect of 
combinations of pg and fiQ, which can be useful in the planning of a pharmaceutical 
trial. One can see that certain combinations of (POJ^Q) yi^ld little net gain, while 
other pairs are better. Note that there is a ridge of (pQ,?ZQ) pairs, from which an ng 
achieving expected maximal gain net of costs for a given pg, can be obtained. The 
surface is not all that variable as a function of ng but it decreases markedly with 
increasing pg. This means that if the prior belief that the new drug treatment is 
effective is large, then the expected net gain is large. Based on what we see in the 
plot, and in Table 3.3 , there is no good reason to sample more than 5 per treatment 
arm, considering the expected gain net of costs. 
Figure 3.4 is a plot for the 5^ procedure of the optimal sample size Uq versus 
the prior pg, for T  =  1,2,3, again fixing Tg = 1 at each stage. At any stage, as pg 
increases, the optimal sample sizes ng generally increase from 0 up to a maximum, 
and then decreases to 0. Of course, it is not possible to have = 1 if rg = 1, since 
t 
is a strictly decreasing function of ^ n^, the accumulating total sample size. 
2=0 
The idea of this plot is to show the optimal sample size conditional on pg and rg if 
one had a truncation time of T = 1,2,3. We see from the plot that the more future 
stages available for sampling that we have, the smaller is our optimal sample size 
ng at the planning stage, and the wider is our initial 'continue-sampling' interval. 
We see that the three curves, corresponding respectively to T = 1,2, and 3, are 
nonincreasing. Numerical results are presented for T = 1, - , 5 in Table 3.4. We 
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see from the table that the optimal sample sizes and corresponding continue/stop 
intervals remain constant for T > 3. This is because, as the truncation horizon 
increases, the optimal sample sizes and corresponding expected net gains converge 
(in this example, quite rapidly). 
Corresponding computations of TIQ versus PQ versus T were done for the Bg 
procedure, and are presented in Figure 3.5 and Table 3.5. There is no difference 
visible to the eye between this plot and Figure 3.4, since the point is infinitesimal 
for r > 1. We see that, for both procedures, there is little change in optimal sample 
size as T increases, and no change for T > 3 as for T = 3. For the purpose of 
optimizing sample size, there is no reason to consider planning a trial with T > 3. 
The most visible observation to be made from the plots is that the optimal sample 
size riQ decreases from 5 to 4 or less as T increases from 1 to 2 for pQ G [.070, .248). 
Figure 3.6 is a plot of 
VoHpa,rolfo)-VoHpo,ro\no) (3.60) 
^o(PO''rol"o) 
the percentage increase in expected net gain for sampling optimally relative to the 
ad hoc sample size ng = 30, for the Bi versus the 5^ procedure, with rg = 1. The 
plot does not include pg > 3 since the denominator in (3.60) is nearly zero just 
past PQ = .3, and, as a function of pQ, the optimal sample size ng drops to zero 
thereafter. This plot shows that the relative increase in expected net gain due to 
sampling optimally, can be large, and that if the prior pQ is in the range [.2, .3), then 
one stands to gain a lot. Data for this plot are given in Table 3.6. Figure 3.7 is the 
same kind of graph for the procedure. The only noticeable difference in percent 
increase in expected net gain between procedures and B^, occurs near pg = 0. 
This is due to the fact that for the B^ procedure, we do not sample at all for very 
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small pQ. Data for this plot are given in Table 3.7. 
Figure 3.8 is a plot of 
[^/(Pbn)l(P0''^0)'"0l -
versus pQ, for .1 < pg < 1, Tq = 1» and ng = 1,30, and 100. This expected net gain 
function is common to both the Bi and procedures. Note that it is never optimal 
to sample if the sample size is 100. The expected net gain is just not high enough 
to make sampling worthwhile. We also note that the expected net gain for mq = 1 is 
always higher than that for ng = 30. Data for this figure are given in Table 3.8. 
Now let us examine the effect of increasing the maximal truncation period T, to 
see if it is an important factor to consider for improving the expected net gain. We 
compared results for T = 2, • • •, 5 to those for T = 1. Figure 3.9 is a plot for the 
procedure of 
^FQ [^l^(Pl'n)l(PO''^o)'"o] -c(«o)' 
versus pQ, for .1 < pg < .6, = 1, and T = 1 to 3. It shows the effect of increasing 
T, the maximal time period at which stopping must occur. To see that the expected 
gain net of costs increases, but not by much, as T increases, one must look at the 
corresponding table of numbers. The expected net gain reaches maximal values for 
all values of pg when T = 3, and (within the precision of our computations) stays 
constant for T > 3. Having the opportunity to have two sampling periods improves 
the expected gain net of costs only slightly, and only for pg in the range (.55, .90]. 
Optimizing on sample size increased expected net gain more so than did increasing 
the time horizon T. This is apparent from Tables 3.9 and 3.3. With the given gain 
and cost structure, we see that there is no real advantage to considering a truncation 
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time beyond T = 2. The same plot was done for the B2 procedure, and is presented 
in Figure 3.10, and Table 3.10. The expected net gains, as a function of T, are nearly 
identical to those for the Bi procedure. This is because both procedures yield nearly 
identical gain functions, for the parameters of this example, since is very small 
for all t. 
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0 . 0 1 . 0 
Figure 3.1: Optimal sample sizes TZQ and associated continue-sampling intervals 
[pO,pPO,i+l)' Bg and T = 1; Example 1 
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Table 3.1: Optimal sample sizes TIQ and associated continue-sampling intervals 
\PQ,vPQ,i+i)^ for and T = 1; Example 1 
Ô i 2 3 4 5 
PQ [.000, .001) [.001, .002) [.002, .009) [.009, .027) [.027, .070) [.070, .532) 
nj 4 3 2 G 
PQ [.532, .654) [.654, .735) [.735, .737) [.737,1.00] 
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4 • 
0 . 0 0 . 2 0 . 4 0 . 6 0 . 8 1 . 0 
Figure 3.2: Optimal sample sizes ng and associated continue-sampling intervals 
b0,z'P0,z+l)' ^nd T = 1; Example 1 
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Table 3.2: Optimal sample sizes ng and associated continue-sampling intervals 
[PO,z'PO,i+l)' and T = 1; Example 1 
"1^ i 2 3 4 5 4 
PQ [.000, .002) [.002, .009) [.009, .027) [.027, .070) [.070, .532) [.532, .654) 
nj 3 2 0 
PQ [.654, .735) [.735, .737) [.737,1.00] 








0390 J75 3 
1 
0 
Figure 3.3: " c("o)' .1 < pq ^ 6 and ng from 1 
to 21 in steps of 2; Example 1 
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Table 3.3: Ep^ [^(Pl,n)l(P0'^0)'"0| -c("o)» for -1 < PO ^ ^ 
and rag from 1 to 21 in steps of 2; Example 1 
PO 0.01 0.02 0.03 0.04 0.05 0.10 0.15 0.20 
1 218.8 185.2 163.4 146.9 133.7 90.5 65.2 48.0 
3 223.0 193.7 175.0 160.8 149.4 111.1 87.1 69.5 
5 220.7 192.4 174.4 160.9 149.9 113.2 89.9 72.6 
7 217.4 189.5 171.8 158.6 147.9 111.9 89.0 71.9 
9 213.8 186.1 168.6 155.5 144.9 109.4 86.8 69.9 
11 210.0 182.5 165.1 152.1 141.6 106.4 83.9 67.1 
13 206.2 178.8 161.4 148.5 138.0 103.1 80.7 64.0 
15 202.3 174.9 157.7 144.8 134.4 99.5 77.3 60.7 
17 198.3 171.1 153.9 141.0 130.6 95.9 73.7 57.2 
19 194.4 167.2 150.0 137.2 126.8 92.2 70.1 53.6 
21 190.5 163.3 146.1 133.3 123.0 88.5 66.4 49.9 
PO 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 
1 35.7 26.5 19.5 14.2 10.0 6.8 4.3 2.4 
3 55.9 44.9 35.8 28.2 21.8 16.4 11.8 7.8 
5 59.0 47.8 38.4 30.4 23.6 17.6 12.4 7.9 
7 58.4 47.2 37.7 29.6 22.5 16.4 10.9 6.2 
9 56.4 45.2 35.7 27.5 20.4 14.1 8.5 3.6 
11 53.7 42.6 33.0 24.8 17.6 11.2 5.6 0.6 
13 50.6 39.5 30.0 21.7 14.5 8.1 2.4 -2.7 
15 47.3 36.2 26.7 18.4 11.2 4.7 -1.0 -6.1 
17 43.9 32.8 23.3 15.0 7.7 1.2 -4.5 -9.7 
19 40.3 29.2 19.7 11.4 4.1 -2.4 -8.1 -13.3 
21 36.6 25.6 16.1 7.8 0.5 -6.0 -11.8 -17.0 
PO 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00 
1 1.0 -0.1 -0.8 -1.3 -1.7 -1.9 -2.0 -2.0 
3 4.5 1.8 -0.5 -2.4 -3.8 -4.9 -5.7 -6.0 
5 4.0 0.7 -2.2 -4.6 -6.6 -8.2 -9.4 -10.0 
7 2.0 -1.7 -4.8 -7.6 -9.9 -11.8 -13.2 -14.0 
9 -0.8 -4.6 -7.9 -10.9 -13.4 -15.4 -17.0 -18.0 
11 -3.9 -7.8 -11.3 -14.4 -17.0 -19.2 -20.9 -22.0 
13 -7.2 -11.3 -14.8 -18.0 -20.7 -23.0 -24.8 -26.0 
15 -10.7 -14.8 -18.4 -21.7 -24.4 -26.8 -28.7 -30.0 
17 -14.3 -18.5 -22.1 -25.4 -28.3 -30.7 -32.7 -34.0 
19 -18.0 -22.2 -25.9 -29.2 -32.1 -34.6 -36.6 -38.0 
21 -21.7 -25.9 -29.7 -33.0 -36.0 -38.5 -40.6 -42.0 
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Figure 3.4: Optimal sample sizes TIQ and associated continue-sampling intervals 
[PO,i'PO,i+l)' and r = 1 to 3; Example 1 
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Table 3.4: Optimal sample sizes ng and associated continue-sampling intervals 
EP0,rf'0,z4-l)) and T = 1 to 5; Example 1 
T^l 
«5 1 2 3 4 5 4 
PO [.000, .002) [.002, .009) [.009, .027) [.027, .070) [.070, .532) [.532, .654) 
«5 3 2 0 
PO [.654,.735) [.735, .737) [.737,1.00] 
T = 2 
nj 1 2 3 4 5 4 
PO [.000, .012) [.012, .051) [.051,.Ill) [.111,.251) [.251, .479) [.479, .598) 
tzq 3 2 0 
PO [.598, .712) [.712, .754) [.754,1.00] 
r = 3 
nj 1 2 3 4 5 4 
PO [.000, .011) [.Oil, .050) [.050, .110) [.110, .250) [.250, .479) [.479, .600) 
nj 3 2 0 
PO [.600, .713) [.713, .754) [.754,1.00] 
T = 4 
ng 1 2 3 4 5 4 
PO [.000, .011) [.Oil, .050) [.050, .110) [.110, .250) [.250, .479) [.479, .600) 
nj 3 2 0 
PO [.600,.713) [.713, .754) [.754,1.00] 
T = 5 
raj 1 2 3 4 5 4 
PO [.000, .011) [.Oil,.050) [.050, .110) [.110, .250) [.250, .479) [.479, .600) 
tiq 3 2 0 
PO [.600, .713) [.713, .754) [.754,1.00] 
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Figure 3.5: Optimal sample sizes TIQ and associated continue-sampling intervals 
[PO,i'PO,i+l)' ^2 r = 1 to 3; .Example 1 
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Table 3.5: Optimal sample sizes TIQ and associated continue-sampling intervals 
[PO,i'PO,î+l)' ^2 r = 1 to 5; Example 1 
nj 0 1 2 3 4 5 
PQ [.000,.001) [.001,.002) [,002,.009) [.009,.027) [.027, .070) [.070,.532) 
ng 4 3 2 0 
PO [.532, .654) [.654, .735) [.735, .737) [.737,1.00] 
r = 2 
nj 0 1 2 3 4 5 
PO [.000, .001) [.001, .011) [.Oil,.050) [.050,.110) [.110, .248) [.248, .482) 
nj 4 3 2 0 
PO [.482, .601) [.601, .714) [.714, .754) [.754,1.00] 
r = 3 
nj 0 1 2 3 4 5 
PO [.000, .001) [.001, .011) [.Oil,.050) [.050,.110) [.110, .248) [.248, .483) 
ng 4 3 2 0 
PO [.483, .601) [.601, .714) [.714, .754) [.754,1.00] 
T = 4 
nj 0 1 2 3 4 5 
PO [.000, .001) [.001,.Oil) [.Oil,.050) [.050,.110) [.110, .248) [.248, .483) 
nj 4 3 2 0 
PO [.483, .601) [.601,.714) [.714, .754) [.754,1.00] 
T = 5 
nj 0 1 2 3 4 5 
PO [.000, .001) [.001,.Oil) [.Oil,.050) [.050,.110) [.110, .248) [.248, .483) 
nj 4 3 2 0 
PO [.483, .601) [.601,.714) [.714, .754) [.754,1.00] 
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Figure 3.6: 0 ol q) 0 (PO' . 100%, the percentage increase in ex-
^0 (P0''^0l"0) 
pected net gain, versus pQ, for the Bi (ng = 30) and Bj" procedures; 
Example 1 
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Table 3.6: ^o'^O-^oK) - percentage 
]i)(%,To|no) 
increase in expected net gain, versus pQ, for the Bi 
[uQ = 30) and procedures; Example 1 
%Gain 29.2 33.1 36.3 39.5 42.5 45.5 48.6 51.9 
PO .01 .02 .03 .04 .05 .06 .07 .08 
%Gain 55.4 59.2 63.1 67.4 72.1 77.1 82.6 88.7 
PO .09 .10 .11 .12 .13 .14 .15 .16 
%Gain 95.5 103.1 111.6 121.4 132.5 145.5 160.6 178.7 
PO .17 .18 .19 .20 .21 .22 .23 .24 
%Gain 200.7 227.7 262.1 307.0 368.2 456.8 
PO .25 .26 .27 .28 .29 .30 
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4 0 0 . 0 0 0  
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Figure 3.7: ^0 (P0>'^0l"0) _ ioO%, the percentage increase in ex-
^(po,Tol"o) 
pected net gain, versus pQ, for the (ng = 30) and Bg procedures; 
Example 1 
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T»Me3.T: a, p«r«.t,g« 
%(po,Toho) 
increase in expected net gain, versus pQ, for the B2 
{riQ = 30) and procedures; Example 1 
%Gain 21.9 33.1 36.3 39.5 42.5 45.5 48.6 51.9 
PQ .01 .02 .03 .04 .05 .06 .07 .08 
%Gain 55.4 59.2 63.1 67.4 72.1 77.1 82,6 88.7 
PO .09 .10 .11 .12 .13 .14 .15 .16 
%Gain 95.5 103.1 111.6 121.4 132.5 145.5 160.6 178.7 
PO .17 .18 .19 .20 .21 .22 .23 .24 
%Gain 200.7 227.7 262.1 307.0 368.2 456.8 
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Figure 3.8: Ep^ [l^(Pl,n)l(P0''''0))"0]"(:("0)' versuspg, for .1 < pg < 1, - 1, 
and ng = 1,30, and 100; Example 1 
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Table 3.8: Ep^ (pj,)|(pg, tq),no]-c(no), versus pQ» for-1 < PO < 
TQ = 1, and ng = 1,30, and 100; Example 1 
PO 0.01 0.02 0.03 0.04 0.05 0.10 0.15 0.20 
1 218.8 185.2 163.4 146.9 133.7 90.5 65.2 48.0 
«0 30 172.6 145.5 128.4 115.7 105.4 71.1 49.2 32.8 
100 32.8 5.9 -11.1 -23.7 -33.8 -67.8 -89.4 -105.6 
PO 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 
1 35.7 26.5 19.5 14.2 10.0 6.8 4.3 2.4 
"0 30 19.6 8.6 -0.9 -9.2 -16.5 -23.0 -28.9 -34.2 
100 -118.7 -129.6 -139.1 -147.3 -154.7 -161.2 -167.2 -172.5 
PO 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.0 
1 1.0 -0.1 -0.8 -1.3 -1.7 -1.9 -2.0 -2.0 
no 30 -38.9 -43.2 -47.1 -50.5 -53.6 -56.2 -58.4 -60.0 
100 -177.4 -181.9 -185.9 -189.5 -192.8 -195.7 -198.1 -200.0 
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Figure 3.9: [vf (Pl,n)l(PO''^o)'"ol " ^0' -1 < PO < •®' 
= 1, r = 1 to 3, and Bf; Example 1 
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Table 3.9; Ef^ (/'b n)l(i'0' ^ o)' "o] " ^ (ng), versus pQ, for 
.1 < PQ < .6, Tg = 1, T = 1 to 5, and Example 1 
PO 0.01 0.02 0.03 0.04 0.05 0.10 0.15 0.20 
1 223.0 193.7 175.1 161.3 150.2 113.2 89.9 72.6 
2 223.0 193.7 175.1 161.3 150.2 113.2 89.9 72.6 
' 3 223.0 193.7 175.1 161.3 150.2 113.2 89.9 72.6 
4 223.0 193.7 175.1 161.3 150.2 113.2 89.9 72.6 
5 223.0 193.7 175.1 161.3 150.2 113.2 89.9 72.6 
PO 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 
1 59.0 47.8 38.4 30.4 23.6 17.6 12.5 8.2 
2 59.0 47.8 38.4 30.4 23.6 17.6 12.7 8.4 
' 3 59.0 47.8 38.4 30.4 23.6 17.6 12.7 8.4 
4 59.0 47.8 38.4 30.4 23.6 17.6 12.7 8.4 
5 . 59.0 47.8 38.4 30.4 23.6 17.6 12.7 8.4 
PO 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00 
1 4.6 1.8 -0.4 -1.3 -1.7 -1.9 -2.0 -2.0 
2 5.0 2.2 0.1 -1.1 -1.5 -1.8 -2,0 -2.0 
3 5.0 2.2 0.1 -1.1 -1.5 -1.8 -2.0 -2.0 
4 5.0 2.2 0.1 -1.1 -1.5 -1.8 -2.0 -2.0 
5 5.0 2.2 0.1 -1.1 -1.5 -1.8 -2.0 -2.0 
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Figure 3.10: Ep^ [l^l^(PbTi)|(P0''^0)'"0j " c(ng), versus pg, for A < pQ < .6, 
Tg = 1, T = 1 to 3, and B^; Example 1 
172 
Table 3.10: Ep^ (Pbn)l(PO'''o)'"o] " c(ng), versus pQ, for 
.1 < PQ < .6, = 1, T = 1 to 5, and Example 1 
PO 0.01 0.02 0.03 0.04 0.05 0.10 0.15 0.20 
1 223.0 193.7 175.1 161.3 150.2 113.2 89.9 72.6 
2 223.0 193.7 175.1 161.3 150.2 113.2 89.9 72.6 
3 223.0 193.7 175.1 161.3 .150.2 113.2 89.9 72.6 
4 223.0 193.7 175.1 161.3 150.2 113.2 89.9 72.6 
5 223.0 193.7 175.1 161.3 150.2 113.2 89.9 72.6 
PO 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 
1 59.0 47.8 38.4 30.4 23.6 17.6 12.5 8.2 
2 59.0 47.8 38.4 30.4 23.6 17.8 12.8 8.5 
3 59.0 47.8 38.4 30.4 23.6 17.8 12.8 8.5 
4 59.0 47.8 38.4 30.4 23.6 17.8 12.8 8.5 
5 59.0 47.8 38.4 30.4 23.6 17.8 12.8 8.5 
PO 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00 
1 4.6 1.8 -0.4 -1.3 -1.7 -1.9 -2.0 -2.0 
2 5.1 2.2 0.1 -1.1 -1.5 -1.8 -2.0 -2.0 
3 5.1 2.2 0.1 -1.1 -1.5 -1.8 -2.0 -2.0 
4 5.1 2.2 0.1 -1.1 -1.5 -1.8 -2.0 -2.0 
5 5.1 2.2 0.1 -1.1 -1.5 -1.8 -2.0 -2.0 
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3.6.4 Example 2: K = 5000, L = 2000, cr^ = 2, TQ = 1, and ng = 30, the 
sample size presented by Berry and Ho 
Berry and Ho presented their procedure, defined here as a procedure, with 
numerical results for K = 5000, L — 2000, = 2, TQ = 1, and ng = 30. It happens 
that for these design parameters, the ad hoc sample size ng = 30 is not far from 
optimal. This can be seen by examining Figure 3.12, a plot of the optimal sample 
size tiq versus pg for the procedure, with TQ fixed at 1. 
Sample size optimization was carried out over values of ng = 5,10,15, • • • (mul­
tiples of five), due to computer memory restrictions. Notice from Figure 3.12 that 
one would sample for all moderate values of pg. In the first example, we saw for 
the ^2 procedure that the lower critical point of the continue/stop interval was 
very small (.001). Because of this, the continue-sampling intervals of the and 
^2 procedures for Example 1 were nearly the same, in contrast to what occurs in 
Example 2. One sees from Figure 3.12 that ng = 35 is the global maximum that 
one would need to consider, when Tg = 1. Data are given for this plot in Table 
3.12. Figure 3.11 is the corresponding plot for the procedure. For pg > .025, we 
see that the ng and their corresponding continue-sampling intervals are identical to 
those for the B^ procedure, as they must be. For pg G [0, .025) the optimal sample 
size ng is positive for the procedure. Data are given for this plot in Table 3.11. 
Figure 3.13 is a contour plot of Ep^ n)l(i'0' ^ o)' "o] —<^("o) ^ ® function 
of both pg and ng for pg 6 [.1, .6] and ng from 5 to 50 in steps of 5. The surface 
is nearly flat as a function of ng, in contrast to the corresponding surface in Figure 
3.3 presented in Example 1. As a function of pg, it decreases markedly. The ridge of 
optimal (pg, ng) pairs is difficult to distinguish. For the parameters of this example, n-
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optimization offers little benefit. The data values from which this plot was computed 
are given in Table 3.13. 
We examined the optimal sample size TIQ as a function of T, the truncation 
time. It is known for the VPRT that UQ decreases as T increases. Figure 3.14 is a 
plot of optimal sample size tiq versus pg, versus the truncation time T, for T < 3. 
This figure is for the procedure, with TQ = 1. The global maximum of optimal 
sample size UQ is 35 when T = 1. This decreases to TIQ = 25 for T > 2. Data for 
r = 1, • • • ,5 are presented in Table 3.14. There are, for any particular pQ, sometimes 
substantial decreases in optimal sample size HQ as T increases from 1 to 2. Optimal 
sample size for T > 3 is nearly the same as for T = 2, indicating that increasing the 
truncation time past 2 will not significantly reduce the optimal sample size ng at the 
planning stage. Nearly identical values were found for the procedure as for the 
B^ procedure. They are presented in Figure 3.15 and Table 3.15. 
Figure 3.16 is a plot of the percentage increase in expected gain net of costs for 
sampling optimally relative to using the ad hoc sample size UQ = 30, with T = 1, 
for the B^ versus the Bi procedure. Values of pQ greater than .95 were excluded 
since it is not optimal to sample at all for values of pQ in (.95,1.0]. The data values 
from which this plot was computed are given in Table 3.16. For values of pg slightly 
less than .95, the percentage increase in gain is greatest, since the denominator of 
(3.60) is near zero for these values. Comparing Figures 3.6 and 3.16 we see that the 
relative advantage of n-optimization can be modest or very large, depending on the 
gain, cost, and variance parameters. It is modest over a large range of pg-values 
for Example 1 but is negligible over most of the range of pg for Example 2. Values 
from which this figure was obtained are given in Table 3.16. Nearly identical values 
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were obtained for the percentage increase in expected gain net of costs for sampling 
optimally relative to using the sample size TIQ = 30, with T = 1, for the versus 
the B2 procedure. They are presented in Figure 3.17 and Table 3.17. 
That the Berry-Ho value ng = 30 is nearly optimal can be seen by plotting 
[V'j^(pi,ri)|(po,7iQ),no] - «(ng) versus pQ for ng = 0,1,30, and 100. We see 
this in Figure 3.18 for the domain pg E [.1,1]. Since all of the gain functions approach 
00 as PQ —» 0, small values of pQ that would distort the scale of the plot were excluded. 
We see that sampling at least one observation yields a substantial increase in expected 
net gain, but it is nearly constant as a function of TIQ for moderate sample sizes (30 
to 100). We also note that, for various values of ng, the expected net gain functions 
of pQ can cross each other. Data for this plot are given in Table 3.18. 
In order to assess the effect on expected net gain of increasing the truncation 
time T, we computed, for the procedure, the function 
^FQ ^(pi,n)l(%,'ro),"o -<"o)' 
versus pg, for .1 < pg < .6, Tg = 1, and T = 1, " ,5. Figure 3.19 is a plot of 
this function of pg and T for T < 3. For any value of pg, the function goes up 
slightly if T is increased from 1 to 2, and remains constant for T > 2. Values for 
T = 1, ",5 are presented in Table 3.19. There is no reason to consider, for the 
purpose of substantially increasing expected net gain, a truncation time greater than 
1. We obtain nearly identical expected net gains for the B^ procedure, as for the B* 
procedure, since for the 5^ procedure, one samples for all but values of pg less than 
.025. Although the expected net gains of the two procedures are nearly identical, the 
lower continue-sampling critical point pjjr of the B^ procedure differs substantially 
from zero. Values for the B^ procedure are presented in Figure 3.20 and Table 3.20. 
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Figure 3.11: Optimal sample sizes ng and associated continue-sampling intervals 
[P0,i)P0,i+l)' -®1 T = 1-, Example 2 
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Table 3.11: Optimal sample sizes TIQ and associated continue-sampling intervals 
b0,i'/'0,i-f-l)' and T = 1; Example 2 
~nj 5 ÏÔ Î5 20 25 30 
PO [.000,.025) [.025,.042) [.042,.070) [.070,.114) [.114,.182) [.182,.309) ' 
nj 35 30 25 20 15 10 
PO [.309, .627) [.627, .771) [.771,.853) [.853, .909) [.909, .948) [.948, .972) 
nQ 5 0 
PQ [.972, .979) [.979,1.00] 
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Figure 3.12: Optimal sample sizes UQ and associated continue-sampling intervals 
lPO,i'PO,é+l)' ^2 1; Example 2 
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Table 3.12: Optimal sample sizes UQ and associated continue-sampling intervals 
b0,i'P0,z-|-l)' and T = 1; Example 2 
~nj Ô ÎÔ Ï5 20 25 3Ô 
PO [.000, .028) [.028, .042) [.042, .070) [.070,.114) [.114, .182) [.182, .309) 
nj 35 30 25 20 15 10 
PO [.309, .627) [.627, .771) [.771,.853) [.853, .909) [.909, .948) [.948, .972) 
tzq 5 0 
PO [.972, .979) [.979,1,00] 
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Figure 3.13; Ef [Fi^(pi,ri)|(po.''o)."o] - <^("0)' k: -1 S PO ^ "0 ' 
to 50 in steps of 5; Example 2 
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Table 3.13: Ep [V^(Pl,ri)|(PO,rg), ng] - c(no), for .1 < PQ < .6 and UQ 0 
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Figure 3.14; Optimal sample sizes «g ^.nd associated continue-sampling intervals 
[P0,i'P0,2+l)' and r = 1 to 3; Example 2 
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Table 3.14: Optimal sample sizes UQ and associated continue-sampling intervals 
tPO,i'PO,z+l)' r = 1 to 5; Example 2 
nj 5 10 15 20 25 30 
PQ [.000, .025) [.025, .042) [.042, .070) [.070,.114) [.114, .182) [.182, .309) 
nj 35 30 25 20 15 10 
PQ [.309, .627) [.627,.771) [.771,.853) [.853, .909) [.909, .948) [.948, .972) 
Rq 5 0 
PQ [.972, .979) [.979,1.00] 
r = 2 
n5 5 10 15 20 25 20 
PQ [.000,.136) [.136, .279) [.279, .401) [.401,.554) [.554, .821) [.821,.846) 
ng 15 10 5 0 
PQ [.846, .927) [.927, .969) [.969, .984) [.984,1.00] 
r = 3 
nj 5 10 15 20 25 20 
PQ [.000, .204) [.204, .278) [.278, .357) [.357, .538) [.538, .819) [.819, .853) 
Uq 15 10 5 0 
PQ [.853, .925) [.925, .969) [.969, .984) [.984,1.00] 
r = 4 
raj 5 10 15 20 25 20 
PQ [.000, .204) [.204, .278) [.278, .357) [.357, .538) [.538, .819) [.819, .853) 
tiq 15 10 5 0 
PQ [.853, .925) [.925, .969) [.969, .984) [.984,1.00] 
T = 5 
nj 5 10 15 20 25 20 
PO [.000, .204) [.204, .278) [.278, .357) [.357, .538) [.538, .819) [.819, .853) 
ng 15 10 5 0 
PO [.853, .925) [.925, .969) [.969,.984) [.984,1.00] 
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Figure 3.15: Optimal sample sizes tzq and associated continue-sampling intervals 
[po z+l)' r = 1 to 3| Example 2 
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Table 3.15: Optimal sample sizes TIQ and associated continue-sampling intervals 
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pected net gain versus pQ, for the Bi (ng = 30) and procedures; 
Example 2 
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Tabla 3.16: . 100%. the 
^o(pO'TOK )  
percentage increase in expected net gain, 
versus pQ, for the Bi (ng = 30) and 
procedures; Example 2 
%Gain 0.3 0.3 0.2 0.2 0.2 0.1 0.1 0.1 
PO .01 .02 .03 .04 .05 .06 .07 .08 
%Gain 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 
PO .09 .10 .11 .12 .13 .14 .15 .16 
%Gain 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
PO .17 .18 .19 .20 .21 .22 .23 .24 
%Gain 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
PO .25 .26 .27 .28 .29 .30 .31 .32 
%Gain 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
PO .33 .34 .35 .36 .37 .38 .39 .40 
%Gain 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
PO .41 .42 .43 .44 .45 .46 .47 .48 
%Gain 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
PO .49 .50 .51 .52 .53 .54 .55 .56 
%Gain 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
PO .57 .58 .59 .60 .61 .62 .63 .64 
%Gain 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
PO .65 .66 .67 .68 .69 .70 .71 .72 
%Gain 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.2 
PO .73 .74 .75 .76 .77 .78 .79 .80 
%Gain 0.3 0.4 0.6 0.7 1.0 1.4 2.0 2.8 
PO .81 .82 .83 .84 .85 .86 .87 .88 
%Gain 3.9 5.4 7.7 12.1 19.8 35.3 82.0 
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1.17: . 100%, the percentage increase In ex-
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pected net gain versus pg, for the B2 ("Q — 30) and 5^ procedures; 
Example 2 
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;.17: (PO'^-OK) ... 
V(f(PO''*ol"o) 
percentage increase in expected net gain, 
versus pQ, for the B2 (^Q ~ 30) and 
procedures; Example 2 
%Gain 0.0 0.0 0.0 0.1 0.2 0.1 0.1 0.1 
PO .01 .02 .03 .04 .05 .06 .07 .08 
%Gain 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 
PO .09 .10 .11 .12 .13 .14 .15 .16 
%Gain 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
PO .17 .18 .19 .20 .21 .22 .23 .24 
%Gain 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
PO .25 .26 .27 ,28 .29 .30 .31 .32 
%Gain 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
PO .33 .34 .35 .36 .37 .38 .39 .40 
%Gain 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
PO , .41 .42 .43 .44 .45 .46 .47 .48 
%Gain 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
PO .49 .50 .51 .52 .53 .54 .55 .56 
%Gain 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
PO .57 .58 .59 .60 .61 .62 .63 .64 
%Gain 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
PO .65 .66 .67 .68 .69 .70 .71 .72 
%Gain 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.2 
PO .73 .74 .75 .76 .77 .78 .79 .80 
%Gain 0.3 0.4 0.6 0.7 1.0 1.4 2.0 2.8 
PO .81 .82 .83 .84 .85 .86 .87 .88 
%Gain 3.9 5.4 7.7 12.1 19.8 35.3 82.0 
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Figure 3.18: Ep^ [Vi^(pl,Ti)l(PO''^o)'«ol " ^ ("o)' versus pg, for .1 < pg < 1' 
Tq = 1, and ng = 0,1,30, and 100; Example 2 
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Table 3.18: Ep^ [l^(Pl,Tl)l(PO'^o),^o] " ^ ("o)' versus PQ, for .1 < pQ < 1, 
Tq = 1, and ng = 0,1,30, and 100; Example 2 
PO 0.01 0.02 0.03 0.04 0.05 0.10 0.15 0.20 
0 11628.7 10265.5 9402.1 8754.2 8228.7 6444.5 5270.6 4366.3 
1 11625.9 10262.8 9399.4 8751.6 8226.4 6444.3 5276.5 4384.1 
30 11579.9 10230.5 9381.6 8748.6 8238.4 6534.4 5445.2 4628.7 
100 11444.5 10098.8 9253.2 8623.2 8115.9 6423.7 5343.7 4534.5 
PO 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 
0 3618.2 2973.9 2404.3 1891.8 1424.6 994.7 596.3 225.0 
1 3655.7 3040.7 2511.8 2052.9 1653.7 1307.5 1009.4 755.7 
30 3971.1 3419.6 2944.9 2529.1 2160.4 1830.8 1534.3 1266.5 
100 3882.6 3335.3 2863.6 2449.7 2081.9 1752.1 1454.3 1184.4 
PO 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.0 
0 -122.3 -448.1 -754.2 -1041.8 -1311.5 -1563.3 -1795.5 -2000.0 
1 543.8 371.0 235.0 133.4 63.2 21.0 1.7 -2.0 
30 1024.4 805.4 607.9 430.7 273.3 136.3 21.6 -60.0 
100 939.1 715.9 513.3 329.8 165.1 19.4 -105.6 -200.0 
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Figure 3.19: [vf (pi,ri)|(po,To)'"ol " versus PQ, for .1 < PQ < -6, 
= 1, T = 1 to 3, and B*-, Example 2 
193 
Table 3.19: Ep^ [^i^(Pl,n)l(PO'''o)'"ol ~ '^^rsus pg, for .1 < pg < 6, 
Tq = 1, T = 1 to 5, and Example 2 
PO 0.01 0.02 0.03 0.04 0.05 0.10 0.15 0.20 
1 11619.8 10260.2 9403.5 8765.2 8251.8 6538.6 5446.3 4628.7 
2 11787.6 10386.0 9506.6 8850.9 8323.4 6570.6 5458.7 4636.3 
' 3 11787.6 10386.0 9506.6 8850.9 8323.4 6570.6 5458.7 4636.3 
4 11787.6 10386.0 9506.6 8850.9 8323.4 6570.6 5458.7 4636.3 
5 11787.6 10386.0 9506.6 8850.9 8323.4 6570.6 5458.7 4636.3 
PO 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 
1 3971.1 3419.6 2945.3 2529.9 2161.4 1831.7 1535.0 1266.8 
2 3971.1 3419.6 2945.3 2529.9 2161.9 1835.9 1541.1 1276.1 
3 3971.1 3419.6 2945.3 2529.9 2161.9 1835.9 1541.1 1276.1 
4 3971.1 3419.6 2945.3 2529.9 2161.9 1835.9 1541.1 1276.1 
5 3971.1 3419.6 2945.3 2529.9 2161.9 1835.9 1541.1 1276.1 
PO 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00 
1 1024.4 805.4 607.9 431.5 276.0 143.6 39.3 -10.0 
2 1035.7 817.6 620.1 442.6 286.1 153.8 47.5 -10.0 
3 1035.7 817.6 620.1 442.6 286.1 153.8 47.5 -10.0 
4 1035.7 817.6 620.1 442.6 286.1 153.8 47.5 -10.0 
5 1035.7 817.6 620.1 442.6 286.1 153.8 47.5 -10.0 
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Figure 3.20: " ^=("0)' versus pQ, for .1 < PQ < 6, 
= 1, T = 1 to 3, and Example 2 
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Table 3.20: [Vi^(Pl,n)l(PO''^o)'"o] ~ 4"o), versus pg, for .1 < pQ < 6, 
Tg = 1, r = 1 to 5, and Example 2 
PQ 0.01 0.02 0.03 0.04 0.05 0.10 0.15 0.20 
1 11619.8 10260.2 9403.5 8765.2 8251.8 6538.6 5446.3 4628.7 
2 11792.5 10392.2 9513.6 8858.4 8331.2 6578.8 5465.4 4642.6 
' 3 11792.5 10392.2 9513.6 8858.4 8331.2 6578.8 5465.4 4642.6 
4 11792.5 10392.2 9513.6 8858.4 8331.2 6578.8 5465.4 4642.6 
5 11792.5 10392.2 9513.6 8858.4 8331.2 6578.8 5465.4 4642.6 
PO 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 
1 3971.1 3419.6 2945.3 2529.9 2161.4 1831.7 1535.0 1266.8 
2 3975.8 3423.6 2948.6 2535.9 2170.8 1843.4 1548.1 1281.9 
3 3975.8 3423.6 2948.6 2536.3 2171.2 1843.9 1548.4 1282.1 
4 3975.8 3423.6 2948.6 2536.3 2171.2 1843.9 1548.4 1282.1 
5 3975.8 3423.6 2948.6 2536.3 2171.2 1843.9 1548.4 1282.1 
PO 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00 




2 1040.5 821.3 622.9 444.7 287.2 154.2 47.6 -10.0 
3 1040.7 821.5 623.1 444.8 287.4 154.4 47.8 -10.0 
4 1040.7 821.5 623.1 444.8 287.4 154.4 47.8 -10.0 
5 1040.7 821.5 623.1 444.8 287.4 154.4 47.8 -10.0 
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3.7 Computational Considerations 
We shall describe in this section the method by which we computed the functions, 
Vf {wt,d,{pt,Tt)y, < = 0,1, - ,T, (3.61) 
where d is the or procedure. These were defined in (3.57) and (3.56), respec­
tively. Backward induction was the basis of all the computations. As we have seen, 
the prior on the distribution of the efficacy 6 is a Gau{vQ, Tq ) distribution. Therefore, 
PO = < 0|:/o,rQ) is given by, 
PO - (3-62) 
Since we are interested in the hypothesis testing problem for a fixed value of TQ, 
we shall examine the function (3.62) for values of pQ over a fine grid on the unit 
interval [0,1]. The parameter i/q is not of immediate interest for testing hypotheses 
but we can obtain it if desired via the relation i/g = —TQ$'"^(pQ). Define r_i to be 
a positive number (say, r_i = 1). Define 
2 2 
r(n_i )^ = 9 for n=0,l,- • • . (3.63) 
We can think of and n_i as a prior variance and sample size, available at stage 
^ = — 1. They are artificial devices necessary to start the backward induction. We 
shall compute (3.61) over a set of values of Tq by setting Tq = r(n_]^)^, and allowing 
n_i to vary. Corresponding to the prior parameter Tq = T(n_2)^, we obtain, for 
a sample size of ng, a posterior parameter = T(n_i + ng)^. It is necessary 
to use TQ incremented over this range of values in order to have tabled values of 
Aq(pq, r(n_i)), necessary for the backward induction to proceed. Hence, Tq takes 
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on a finite set of values that are not equally spaced, and we compute (3.61) over a 
grid of (PQ, 7^)-values that could equally be indexed by (pg»"—l)- Making the prior 
parameter TQ discrete, requires less storage; values only need to be interpolated in 
PQ, instead of a more complicated fitting of values over the (pQ, TQ)-plane. But if one 
wanted certain rg-values one would have to interpolate over TQ as well. 
Recall the formula for ('ke predictive density of S at time t 
given in (3.14). We have seen in Proposition 3.3 that for i = 0, • • *, T — 1, 
q {wf^i \u i ,  Tf )  is a density from a Gau{vi, rf + (a^/m^)) distribution. (3.64) 
We have also seen in (3.10), (3.11), and Proposition 3.2 that, 
t 
+ T-Q E  ^I-M 
H = R~^ ' (365) 
and 
^0 Z "i-l + 
2=1 
2 _ 




Now consider the and procedures. (The computational methods for the 
Bi and Bg procedures are obtained by constraining the sample sizes {n^} to be a 
fixed ad hoc value in the and B^ procedures, respectively.) Let ipQ be the index 
of pQ over a grid on [0,1]. We have a vector of values of pQ = p(ipQ). Let n be 
the index of T(n)^; that is, for convenience replace n_i with n. Let V{ipQ,n) be 
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a matrix of values of the expected net gain function (3.61). We shall describe how 
the function (3.61) is saved in this array at stage t, and then used to compute the 
function (p(_i,Tf_i)). 
^2 Procedure 
T  =  0 :  
Letting ag = $""^(^0), we compute, 
V{IPQ,N) 
= max |o, { -L)PQ + (1 - />o)Jt^r(n) ^ 
= moz {0, AQ(po, T(n))} , (3.67) 
for pq over a grid, and for n over a set of values. This yields Vq^(û;q,(/, (poi^o))) 
where tDg = —TQ$"^(pQ), and TQ = r(n). 
r = 1 : 
We compute, over the (pQ,n) grid, 
= max jo, (-£)po + (1 -
= moz {0, AQ(PQ, TQ), , (3.68) 
where 
A = max 
«0 ^ 
+ "o))''" - Z'-O j ' (3-69) 
and âj, a(pQ), and b are defined in (3.34),(3.39), and (3.40) respectively. The lower 
bound of the integration is Sj, the root of, 
(-L)$(s) + KT{N + no) [<?!'(s) - 5(1 - $(&))]. 
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It is obtained by the Newton-Raphson method, as described in (3.33). Note that 
rj = r(n + ng), by (3.66). The function /ii($(u),T(n + ng)) in (3.69) is obtained 
by interpolating the tabled values V(ipQ,n + ng) ^(^PO + + ng), where ipg 
is chosen such that p(ipQ) < $(«) < p(ipQ + 1). Finally, we store the value (3.68) 
in V(ipQ,n). In order to interpolate with tabled values, we require that the values 
n + ng must be among those n-values used to compute V(ipQ, n) when T = 0. 
T = t : 
We have stored in the array V(ipQ,n) values of, 
^T-t+l (^T-^+1 '  4 '  iPT-t+l '  '^T-t+l ))• 
We use these, as before, to obtain, 
4' (PT-T^ T-<)) = {O, HJ'_FIPJ^_F, (3-70) 
where 
B =  max {— 2nj<_f  
^T-T ^ 1 
^T-T( '^T-T+H^HIPT-T+H'^T-T+LMPT-T' '^T-T)^^T-T]}-
To obtain (3.70), we need to compute B. This requires numerical integrations of, 
for sample sizes ny_^. This is carried out by taking as summands in the computation 
of this integral, the q-density (3.14) times interpolated tabled values of, 
' 4' (PT-i+1 ' "^T-i+l ))' 
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loading up the V(zpQ, n) array with these products for use at the next stage. Working 
backward, we obtain, after T stages, (iDg, (PQ* ^o))-
B* Procedure 
We proceed with the backward induction, as for the Procedure, replacing 
(3.68) by, 
Vo^(ù;i,4,(PO''^("))) =moa;{0,A} (3.71) 
and (3.70) by, 
= rnax{0 ,B} .  (3.72) 
3.8 Conclusions 
Several observations can be made about the two numerical examples presented. 
The different sets of parameters of the examples illustrate various ideas about the 
four procedures. 
Comparing the two examples, we see that n-optimization can yield a sharp in­
crease in expected net gain in Example 1 but not in Example 2. Indeed, the param­
eters K, L, and cr^ of Example 1 were chosen in order to illustrate the advantage of 
n-optimization. The contour plots of expected net gain as a function of pg &nd the 
sample size ng, computed for the case T = 1, are intended to show a ridge tracing 
out optimal pairs (po>"o)- The ridge is almost neghgible for Example 2 (Figure 
3.13), but is more pronounced for Example 1 (Figure 3.3). These comments also in­
dicate the difference between the pair of procedures (B^, ^2) the pair (B'^^B^)-
Sample-size optimization can yield a substantial increase in expected net gain, but 
need not, depending on the parameters K, L, and <7 . 
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As the truncation time T is increased, it known for the VPRT that the expected 
net gain is nondecreasing. It is conjectured that this is also true for the problem solved 
in this chapter. The increases in expected net gain, as T increases, are slight for both 
the and 5^ procedures, and are undetectable from the three-dimensional graphs 
of expected net gain versus pg versus T for T = 1,2,3 (Figures 3.9, 3.10, 3.19, and 
3.20). In order to examine this phenomenon, we must look at the associated tables 
of numbers. For Example 1, we see virtually no change in expected net gain as T 
increases, for both the and B^ procedures (Tables 3.9 and 3.10), Apparently, the 
maximum gain attainable is reached after just one sampling period. For Example 2 
we see, for both the B^ and B^ procedures, a slight increase in expected net gain if we 
had two sampling periods available, as compared to that attained for T = 1 (Tables 
3.19 and 3.20). We also note for this example that beyond T = 2, the expected net 
gain does not change. 
Finally, we examine the difference between the pair of procedures (Bi,B*) and 
the pair (B2, B^)- The Bi procedure specifies that a sample is taken if the expected 
net gain attained by sampling exceeds zero (zero is the gain attained by concluding 
that JIQ : 6 < 0 is true). The B^ procedure is the same as that of Bj, except that 
it employs the optimal sample size Uq. The B2 and B^ procedures also allow for 
early stopping due to the conclusion that Hi : S > 0 is true. That is, they allow for 
"two-sided" early stopping, to conclude either JIQ or BI. The expected net gain for 
B2 is at least as large as that of Bi, since the former maximizes over the expected net 
gain function for Bi, and the gain function for stopping and deciding Bi is true. The 
increase in expected net gain by using B2 (B^) instead of Bi (B^) is very modest for 
both examples. We see this for Example 1 by examining Tables 3.9 and 3.10 for the 
202 
and procedures, respectively. The expected net gains are identical for T = 1 
and values of pQ exceeding as they must be. For small pg and T = 1, we see a 
slight increase in expected net gain for B^ relative to B^. This same phenomenon 
holds for T = 2. As noted earlier, the expected net gain functions remain constant as 
a function of T for T > 2. The same observations hold for Example 2 by examining 
Tables 3.19 and 3.20 for the and B^ procedures, respectively. 
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